Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
47.0 /100
Rank 54 out of 131 Industries -
Advance/Decline
98/250
-
No. of Companies348
-
Avg. Market Cap12,689
-
Price to Earning Ratio9.85
-
Price to Earning Growth Ratio0.77
-
Price to Book Ratio33.04
-
Return on Equity53.88
-
Return on Capital Employed-
-
Return on Assets12.08
-
Dividend yield 1 year %0.84 %
-
Net Profit Growth Annual YoY %-0.77 %
-
Net Profit Growth Qtr YoY %-64.05 %
-
Net Profit Growth Qtr QoQ %-71.40 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
390,432.9
|
220.9
|
L
 0.2%
H
219.6
221.9
|
L
 1.3%
H
215.9
226.9
|
L
 -4.3%
H
210.0
237.0
|
L
 -1.9%
H
210.0
239.3
|
L
 26.1%
H
164.4
244.8
|
L
 51.0%
H
131.0
244.8
|
L
 115.6%
H
101.9
244.8
|
L
 302.4%
H
51.6
244.8
|
| Adc Therapeutics SA |
|
458.3
|
3.7
|
L
 -1.6%
H
3.6
3.8
|
L
 -2.6%
H
3.3
3.8
|
L
 5.7%
H
3.3
3.9
|
L
 -19.7%
H
2.9
4.8
|
L
 124.2%
H
1.1
4.8
|
L
 -26.7%
H
0.4
6.0
|
L
 -87.0%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
4,338.2
|
13.8
|
L
 -2.2%
H
13.7
14.0
|
L
 1.6%
H
13.3
15
|
L
 6.9%
H
12.3
15
|
L
 32.3%
H
10.0
15
|
L
 58.1%
H
6.7
15
|
L
 544.9%
H
1.2
15
|
L
 186.9%
H
1.2
15
|
L
 -63.2%
H
1.2
38.4
|
| Annovis Bio Inc |
|
74.2
|
2.8
|
L
 -0.4%
H
2.7
2.9
|
L
 -8.5%
H
2.7
3.1
|
L
 -20%
H
2.7
4.1
|
L
 27.3%
H
1.9
5.5
|
L
 -42.7%
H
1.1
5.5
|
L
 -81.6%
H
1.1
23.9
|
L
 -71.9%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,056.4
|
5.6
|
L
 -0.7%
H
5.5
5.6
|
L
 -15.5%
H
5.5
6.2
|
L
 -22.2%
H
5.5
8
|
L
 -5.9%
H
5.5
8
|
L
 -25.7%
H
4.3
8.7
|
L
 -33.8%
H
4.0
11.5
|
L
 -78.2%
H
4.0
34.8
|
L
 -93.8%
H
4.0
101.4
|
| Bristol-Myers Squibb |
|
111,131.8
|
54.6
|
L
 0.6%
H
54.3
54.9
|
L
 -0.6%
H
54.2
56.1
|
L
 0.9%
H
52.1
57.0
|
L
 28.2%
H
43.2
57.0
|
L
 -7.6%
H
42.5
63.3
|
L
 -24.7%
H
39.4
75.2
|
L
 -11.1%
H
39.4
81.4
|
L
 -12.2%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
607.7
|
11.6
|
L
 -2.8%
H
11.5
12.1
|
L
 -4.3%
H
11.5
12.4
|
L
 -5.3%
H
10.6
14.1
|
L
 23.1%
H
9.0
14.1
|
L
 7.1%
H
4.0
14.1
|
L
 -14.1%
H
1.4
16.7
|
L
 -89.2%
H
1.4
127.2
|
L
 -66.5%
H
1.4
137.6
|
| GSK PLC (ADR) |
|
103,253.4
|
51.2
|
L
 1.1%
H
51.1
51.4
|
L
 5.2%
H
48.6
51.4
|
L
 4.2%
H
47.6
51.5
|
L
 11.5%
H
45.8
51.5
|
L
 46.0%
H
32.4
51.5
|
L
 45.0%
H
31.7
51.5
|
L
 35.0%
H
28.5
51.5
|
L
 21.8%
H
28.5
51.5
|
| Johnson & Johnson |
|
544,283.9
|
225.9
|
L
 -0.6%
H
225.7
228.5
|
L
 3.4%
H
217.8
230
|
L
 8.8%
H
200.9
230
|
L
 21.1%
H
185.1
230
|
L
 49.5%
H
141.5
230
|
L
 34.3%
H
140.7
230
|
L
 38.5%
H
140.7
230
|
L
 116.3%
H
99.8
230
|
| Eli Lilly |
|
920,401.5
|
1,028.4
|
L
 0.4%
H
1023.0
1039.2
|
L
 -5.4%
H
1004.1
1084.3
|
L
 -4.7%
H
1004.1
1134.0
|
L
 26.4%
H
812.3
1134.0
|
L
 27.9%
H
623.8
1134.0
|
L
 200.6%
H
309.2
1134.0
|
L
 394.5%
H
178.6
1134.0
|
L
 1200.1%
H
64.2
1134.0
|
| Merck & Company |
|
269,820.7
|
108.7
|
L
 0.3%
H
108.1
109.5
|
L
 -0.4%
H
106.0
109.9
|
L
 2.0%
H
104.4
112.9
|
L
 25.6%
H
82.0
112.9
|
L
 10.6%
H
73.3
112.9
|
L
 3.2%
H
73.3
134.6
|
L
 47.8%
H
68.4
134.6
|
L
 124.8%
H
45.8
134.6
|
| Novo Nordisk (ADR) |
|
261,498.8
|
58.9
|
L
 -0.8%
H
58.6
59.3
|
L
 -5.4%
H
58.6
64.2
|
L
 14.3%
H
50.6
64.2
|
L
 14.6%
H
43.1
64.2
|
L
 -30.0%
H
43.1
93.8
|
L
 -14.8%
H
43.1
148.2
|
L
 69.1%
H
33.3
148.2
|
L
 110.7%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
286,610.0
|
149.4
|
L
 0.3%
H
149.3
150.0
|
L
 3.0%
H
145.3
152.5
|
L
 7.3%
H
135.6
152.5
|
L
 22.6%
H
122.0
152.5
|
L
 45.1%
H
97.7
152.5
|
L
 66.9%
H
80.0
152.5
|
L
 65.1%
H
74.1
152.5
|
L
 116.7%
H
59.2
152.5
|
| Organon & Co. |
|
2,165.7
|
8.3
|
L
 -3.1%
H
8.3
8.5
|
L
 -14.5%
H
8.3
9.9
|
L
 17.2%
H
7.1
9.9
|
L
 31.4%
H
6.2
9.9
|
L
 -47.4%
H
6.2
17.2
|
L
 -72.2%
H
6.2
30.5
|
L
H
6.2
39.5
|
L
H
6.2
39.5
|
| Prestige Consumer Healthcare Inc |
|
3,085.1
|
64.2
|
L
 0.4%
H
63.6
64.4
|
L
 -5.3%
H
62.7
67.7
|
L
 0.7%
H
60.2
68.3
|
L
 5.7%
H
57.3
68.3
|
L
 -18.6%
H
57.3
90.0
|
L
 -2.3%
H
56.0
90.0
|
L
 60.4%
H
39.4
90.0
|
L
 37.4%
H
26.3
90.0
|
| Pfizer |
|
147,714.7
|
26.0
|
L
 -0.5%
H
25.9
26.2
|
L
 1.2%
H
25.5
26.8
|
L
 3.9%
H
24.8
26.8
|
L
 7.0%
H
23.9
26.8
|
L
 -2.4%
H
20.9
27.7
|
L
 -40.7%
H
20.9
44.5
|
L
 -27.6%
H
20.9
61.7
|
L
 -10.0%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,899.2
|
13.8
|
L
 0.4%
H
13.7
14.0
|
L
 -8.5%
H
13.6
15.2
|
L
 -0.8%
H
13.6
15.4
|
L
 -35.2%
H
12.2
21.3
|
L
 -44.1%
H
12.2
30.9
|
L
 -62.9%
H
12.2
40.3
|
L
 -67.7%
H
12.2
50.9
|
L
 -90.5%
H
12.2
147.6
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,064.8
|
13.3
|
L
 0.2%
H
13.3
13.3
|
L
 -3.1%
H
13.1
13.8
|
L
 -5.8%
H
12.8
14.2
|
L
 -0.9%
H
12.8
14.3
|
L
 -1.7%
H
12.3
16.2
|
L
 24.6%
H
10.5
74.9
|
L
 8.4%
H
9.6
74.9
|
L
 47.8%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
54,148.6
|
17.1
|
L
 -0.2%
H
17.1
17.2
|
L
 7.5%
H
16.0
17.3
|
L
 8.8%
H
15.5
17.3
|
L
 24.5%
H
13.0
17.3
|
L
 28.8%
H
13.0
17.3
|
L
 6.9%
H
12.6
17.3
|
L
 -2.8%
H
12.3
20.0
|
L
 -28.1%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
38,157.7
|
32.5
|
L
 -1.6%
H
32.4
33
|
L
 2.8%
H
30.9
33.4
|
L
 3.1%
H
30.5
33.4
|
L
 60.8%
H
20.0
33.4
|
L
 75.5%
H
12.5
33.4
|
L
 213.4%
H
7.1
33.4
|
L
 176.1%
H
6.8
33.4
|
L
 -47.1%
H
6.1
62.8
|
| Zoetis (Class A) |
|
53,579.5
|
121.6
|
L
 -0.1%
H
120.1
121.9
|
L
 -2.3%
H
120.1
126.3
|
L
 -3.5%
H
120.1
131.1
|
L
 -15.5%
H
115.3
145.0
|
L
 -28.6%
H
115.3
177.4
|
L
 -26.4%
H
115.3
201.9
|
L
 -21.2%
H
115.3
249.3
|
L
 182.4%
H
38.3
249.3
|
| Biohaven Ltd |
|
1,569.7
|
11.8
|
L
 -2.2%
H
11.7
12.3
|
L
 -14.0%
H
11.7
14.0
|
L
 2.5%
H
9.3
14.0
|
L
 -34.7%
H
7.5
18.6
|
L
 -68.7%
H
7.5
44.3
|
L
 -37.1%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Abeona Therapeutics Inc |
|
271.5
|
5.0
|
L
 -1.4%
H
5.0
5.2
|
L
 -6.5%
H
4.8
5.4
|
L
 -6.7%
H
4.8
5.7
|
L
 0.4%
H
4
5.7
|
L
 -8.1%
H
3.9
7.5
|
L
 89.1%
H
2.2
9.0
|
L
 -89.5%
H
2.2
94.8
|
L
 -92.3%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
1,662.9
|
34.4
|
L
 -2.6%
H
34.0
35.5
|
L
 -3.3%
H
33.8
36.3
|
L
 11.2%
H
25.2
36.5
|
L
 24.4%
H
25.2
36.5
|
L
 184.6%
H
5.5
36.5
|
L
 28.9%
H
2.2
53.9
|
L
 -31.8%
H
2.2
66
|
L
 -95.8%
H
2.2
939.6
|
| Acumen Pharma Inc |
|
163.5
|
2.7
|
L
 -3.2%
H
2.7
2.8
|
L
 35.7%
H
1.9
3.1
|
L
 35%
H
1.7
3.1
|
L
 19.5%
H
1.5
3.1
|
L
 72.0%
H
0.9
3.1
|
L
 -50.5%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
792.4
|
4.1
|
L
 -0.2%
H
4.1
4.2
|
L
 -1.0%
H
4.0
4.2
|
L
 -12.7%
H
3.7
5.1
|
L
 -10.6%
H
3.7
5.1
|
L
 21.9%
H
2.7
5.1
|
L
 40.6%
H
1.7
5.1
|
L
 9.0%
H
1.7
6.5
|
L
 31.2%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
49.1
|
2.0
|
L
 -2.9%
H
2.0
2.1
|
L
 -2.9%
H
2
2.1
|
L
 -12.6%
H
2.0
2.4
|
L
 -27.1%
H
2.0
3.1
|
L
 288.5%
H
0.4
5.5
|
L
 -73.4%
H
0.4
9.6
|
L
 -96.0%
H
0.4
299.5
|
L
 -99.9%
H
0.4
378
|
| Acadia Pharma Inc |
|
4,275.2
|
25.3
|
L
 -1.7%
H
25.1
25.8
|
L
 -8.1%
H
25.1
27.8
|
L
 -7.3%
H
25.1
27.8
|
L
 12.2%
H
20.6
28.4
|
L
 37.6%
H
13.4
28.4
|
L
 36.1%
H
13.4
33.9
|
L
 -47.4%
H
12.2
52.8
|
L
 22.1%
H
12.2
58.7
|
| Adicet Bio Inc |
|
80.7
|
8.4
|
L
 -1.1%
H
8.3
8.5
|
L
 0.1%
H
8.2
9
|
L
 6.9%
H
7.6
9.1
|
L
 -30.0%
H
7.4
13.0
|
L
 -41.7%
H
7.2
17.4
|
L
 -94.1%
H
7.2
152.4
|
L
 -95.7%
H
7.2
349.9
|
L
H
7.2
349.9
|
| Achieve Life Sciences Inc |
|
224.1
|
4.2
|
L
 -3%
H
4.2
4.5
|
L
 -23.7%
H
4.2
5.7
|
L
 -5.2%
H
4.2
6.0
|
L
 -15.0%
H
3.8
6.0
|
L
 30.8%
H
1.8
6.0
|
L
 -14.8%
H
1.8
10.3
|
L
 -65.5%
H
1.8
16.1
|
L
 -99.7%
H
1.8
3123.8
|
| AC Immune SA |
|
336.0
|
3.3
|
L
 -1.8%
H
3.3
3.4
|
L
 -8.0%
H
3.3
3.9
|
L
 2.8%
H
3.1
3.9
|
L
 -13.0%
H
2.5
3.9
|
L
 26.5%
H
1.4
4
|
L
 41.5%
H
1.4
5.1
|
L
 -44.1%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
395.5
|
3.7
|
L
 6.4%
H
3.6
3.8
|
L
 -19.4%
H
3.4
4.8
|
L
 21.3%
H
2.5
4.9
|
L
 56.0%
H
2.1
4.9
|
L
 54.7%
H
1.1
4.9
|
L
 -79.1%
H
0.6
18.5
|
L
 -82.4%
H
0.6
30.4
|
L
 -83.6%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
57.7
|
1.8
|
L
 -2.7%
H
1.8
1.9
|
L
 -9.9%
H
1.8
2.1
|
L
 -22.5%
H
1.6
3.6
|
L
 -3.2%
H
1.6
3.6
|
L
 -67.0%
H
1.1
8
|
L
 -87.4%
H
1.1
25.5
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
16.4
|
1.0
|
L
 -2.0%
H
1.0
1.0
|
L
 -4.0%
H
1.0
1.0
|
L
 -9.4%
H
1.0
1.3
|
L
 -21.1%
H
1.0
1.6
|
L
 94%
H
0.4
1.6
|
L
 -51.3%
H
0.4
2.3
|
L
 -97.8%
H
0.4
58.8
|
L
 -98.7%
H
0.4
115
|
| Grace Therapeutics Inc |
|
55.1
|
3.6
|
L
 1.4%
H
3.5
3.6
|
L
 -6.3%
H
3.5
3.9
|
L
 5.0%
H
3.4
3.9
|
L
 13.7%
H
3.0
3.9
|
L
 2.3%
H
1.8
3.9
|
L
 -16.8%
H
1.7
5.0
|
L
 -88.6%
H
1.7
58.6
|
L
 -95.2%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
5.7
|
2.4
|
L
 -2.8%
H
2.4
2.6
|
L
 -12.6%
H
2.4
2.9
|
L
 -17.6%
H
2.4
3.5
|
L
 -57.2%
H
2.4
5.9
|
L
 -83.4%
H
2.4
21
|
L
 -96.8%
H
2.4
176.4
|
L
H
2.4
176.4
|
L
H
2.4
176.4
|
| Adial Pharma Inc |
|
5.8
|
0.2
|
L
H
0.2
0.2
|
L
 -8.7%
H
0.2
0.2
|
L
 -8.7%
H
0.2
0.3
|
L
 -40%
H
0.2
0.4
|
L
 -75.6%
H
0.2
1.3
|
L
 -97.3%
H
0.2
15
|
L
 -99.6%
H
0.2
127
|
L
H
0.2
236
|
| Agios Pharma Inc |
|
1,597.2
|
27.4
|
L
 -0.8%
H
27.1
27.9
|
L
 -4.4%
H
27.1
29.9
|
L
 0.9%
H
26.3
29.9
|
L
 -34.7%
H
22.2
46
|
L
 -18.8%
H
22.2
46
|
L
 -10.9%
H
19.8
62.6
|
L
 -41.7%
H
16.8
62.6
|
L
 -35.1%
H
16.8
99.8
|
| Akebia Therapeutics Inc |
|
376.8
|
1.4
|
L
 -2.1%
H
1.4
1.5
|
L
 -1.4%
H
1.4
1.5
|
L
 -12.4%
H
1.3
1.7
|
L
 -32.4%
H
1.3
2.3
|
L
 -38.3%
H
1.3
4.1
|
L
 111.9%
H
0.5
4.1
|
L
 -56.2%
H
0.2
5.1
|
L
 -80.6%
H
0.2
20.3
|
| Aligos Therapeutics Inc |
|
48.6
|
7.9
|
L
 -2.8%
H
7.9
7.9
|
L
 -7.6%
H
7.7
9.0
|
L
 -18.2%
H
7.6
10.5
|
L
 -8.4%
H
5.8
13.7
|
L
 -67.0%
H
3.8
29.5
|
L
 -83.3%
H
3.8
52.5
|
L
 -98.9%
H
3.8
875
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
5,727.9
|
34.7
|
L
 -0.5%
H
34.3
35.0
|
L
 2.2%
H
32.5
35.3
|
L
 23.9%
H
27.5
35.3
|
L
 10.3%
H
27.5
36.3
|
L
 9.9%
H
25.2
36.5
|
L
 19.5%
H
22.0
36.5
|
L
 65.3%
H
18.0
36.5
|
L
 8.4%
H
12.0
71.2
|
| Allarity Therapeutics Inc |
|
16.4
|
1.0
|
L
 -1.9%
H
1.0
1.0
|
L
 -17.7%
H
1.0
1.3
|
L
 -2.9%
H
1
1.3
|
L
 -28.2%
H
1.0
1.5
|
L
 -27.7%
H
0.6
2.1
|
L
 -100.0%
H
0.1
7560
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
44,770.7
|
338.9
|
L
 -2.3%
H
336.4
346.5
|
L
 -8.4%
H
336.4
371.3
|
L
 -15.0%
H
336.4
427.1
|
L
 -29.6%
H
336.4
479.8
|
L
 23.7%
H
205.9
495.6
|
L
 46.5%
H
142.0
495.6
|
L
 125.2%
H
117.6
495.6
|
L
 391.6%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
36.8
|
1.4
|
L
 -2.1%
H
1.4
1.4
|
L
 4.5%
H
1.3
1.6
|
L
 22.8%
H
1.0
1.6
|
L
 -9.7%
H
1.0
2.2
|
L
 -43.8%
H
1.0
3.0
|
L
 -51.2%
H
1.0
7.4
|
L
 -96.2%
H
1.0
46
|
L
H
1.0
309.6
|
| Alzamend Neuro Inc |
|
7.9
|
2.1
|
L
 3.0%
H
2.0
2.1
|
L
 -8.8%
H
2.0
2.4
|
L
 6.7%
H
1.7
2.5
|
L
 -15.5%
H
1.7
2.7
|
L
 -79.4%
H
1.7
10.7
|
L
 -99.8%
H
1.7
1071.9
|
L
H
1.7
45292.5
|
L
H
1.7
45292.5
|
| Amylyx Pharma Inc |
|
1,613.2
|
14.7
|
L
 -1.1%
H
14.6
15
|
L
 -9.5%
H
14.2
16.5
|
L
 20.5%
H
10.8
17.5
|
L
 5.8%
H
10.8
17.5
|
L
 324.6%
H
2.6
17.5
|
L
 -64.1%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
1,214.1
|
26.4
|
L
 1.0%
H
26.0
26.4
|
L
 1.1%
H
25.6
26.7
|
L
 -1.4%
H
25.4
29.5
|
L
 9.0%
H
23.7
29.5
|
L
 -27.5%
H
20.4
37.0
|
L
 -13.6%
H
20.4
67.7
|
L
 45.3%
H
16.9
67.7
|
L
 119.3%
H
10.5
67.7
|
| Anebulo Pharma Inc |
|
36.2
|
0.9
|
L
H
0.8
0.9
|
L
 -20%
H
0.8
1.1
|
L
 -11.1%
H
0.8
1.2
|
L
 -67.5%
H
0.8
2.7
|
L
 -42.9%
H
0.8
3.4
|
L
 -66.9%
H
0.8
4.1
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
| Annexon Inc |
|
948.0
|
6.4
|
L
 -2.5%
H
6.3
6.8
|
L
 -8.6%
H
6.3
7.2
|
L
 27.2%
H
4.5
7.2
|
L
 99.4%
H
2.5
7.2
|
L
 54.4%
H
1.3
7.2
|
L
 -14.7%
H
1.3
8.4
|
L
 -71.1%
H
1.3
38.0
|
L
H
1.3
38.0
|
| Apollomics Inc (Class A) |
|
38.1
|
17.8
|
L
 -0.9%
H
17.8
17.8
|
L
 -5.0%
H
17.5
20.5
|
L
 -15.0%
H
17.5
23
|
L
 25.9%
H
10.0
27.0
|
L
 104.6%
H
3.7
42.1
|
L
 -98.3%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharma Inc |
|
2,875.9
|
22.7
|
L
 -1.4%
H
22.6
23.4
|
L
 3.3%
H
21.1
23.8
|
L
 -9.7%
H
19.3
27.5
|
L
 -24.4%
H
18.8
27.5
|
L
 -22.9%
H
16.1
30.6
|
L
 -56.9%
H
16.1
94.8
|
L
 -48.7%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Applied Therapeutics Inc |
|
14.4
|
0.1
|
L
H
0.1
0.1
|
L
 -9.1%
H
0.1
0.1
|
L
H
0.1
0.1
|
L
 -91.8%
H
0.1
1.2
|
L
 -81.5%
H
0.1
1.5
|
L
 -91.7%
H
0.1
10.6
|
L
 -99.5%
H
0.1
29.8
|
L
H
0.1
57.4
|
| Aptorum Grp Ltd (Class A) |
|
6.8
|
0.8
|
L
 2.4%
H
0.8
0.9
|
L
 -14.3%
H
0.8
1.0
|
L
 -22.2%
H
0.8
1.1
|
L
 -42.5%
H
0.8
1.7
|
L
 -25%
H
0.7
4.5
|
L
 -83.6%
H
0.5
17.5
|
L
 -97.4%
H
0.5
45.6
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
4.7
|
0.7
|
L
 13.6%
H
0.6
0.7
|
L
 -20.2%
H
0.6
0.9
|
L
 -27.2%
H
0.6
1
|
L
 -53.8%
H
0.6
1.5
|
L
 -81.9%
H
0.6
4.7
|
L
 -92.9%
H
0.6
11.3
|
L
 -99.4%
H
0.6
169.2
|
L
H
0.6
1062.2
|
| Aquestive Therapeutics Inc |
|
384.3
|
3.2
|
L
 -0.3%
H
3.1
3.2
|
L
 -3.1%
H
3.1
3.5
|
L
 -51.3%
H
3.1
6.6
|
L
 -51.4%
H
3.1
6.9
|
L
 1.6%
H
2.1
7.6
|
L
 253.9%
H
0.7
7.6
|
L
 -40.5%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
210.8
|
7.4
|
L
 -2.0%
H
7.3
7.6
|
L
 -2.2%
H
7.2
7.8
|
L
 20.5%
H
6.0
7.9
|
L
 -21.4%
H
5.9
10.1
|
L
 -55.9%
H
5.9
24.2
|
L
 -64.0%
H
5.9
45
|
L
 -89.8%
H
5.9
89.2
|
L
 -79.3%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,863.6
|
7.7
|
L
 -2.3%
H
7.6
7.9
|
L
 -3.3%
H
7.6
8.4
|
L
 32.7%
H
5.5
8.4
|
L
 54.6%
H
4.9
8.4
|
L
 40.0%
H
3.2
8.4
|
L
 169.1%
H
2.8
10.1
|
L
 13.0%
H
0.5
10.1
|
L
 -26.3%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,104.0
|
25.3
|
L
 -1.5%
H
25.2
25.6
|
L
 -4.9%
H
25.2
27.0
|
L
 -11.3%
H
25.1
30.8
|
L
 0.2%
H
22.3
31.8
|
L
 84.7%
H
11.1
31.8
|
L
 53.0%
H
1.8
31.8
|
L
 -7.1%
H
1.8
38.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
3.4
|
1.7
|
L
H
1.6
1.8
|
L
 -2.9%
H
1.6
1.9
|
L
 35.5%
H
1.2
1.9
|
L
 -52.4%
H
1.2
3.5
|
L
 -76.3%
H
1.2
28.6
|
L
 -91.3%
H
1.2
28.6
|
L
 -98.1%
H
1.2
330.3
|
L
H
1.2
15552
|
| Assembly Biosciences Inc |
|
397.2
|
25.1
|
L
 -2.3%
H
24.7
25.7
|
L
 -9.1%
H
24.7
28.6
|
L
 -24.6%
H
24.7
34.7
|
L
 -19.0%
H
24.7
39.7
|
L
 81.2%
H
7.8
39.7
|
L
 22.4%
H
7.7
39.7
|
L
 -62.5%
H
7.7
84.2
|
L
 -59.1%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
865.8
|
6.9
|
L
 -4.4%
H
6.8
7.2
|
L
 -14.9%
H
6.8
8.6
|
L
 21.2%
H
5.2
8.6
|
L
 -33.3%
H
5.2
11.1
|
L
 27.4%
H
3.7
14.5
|
L
 329.8%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
73.2
|
11.4
|
L
 -2.8%
H
11.4
11.6
|
L
 -2.1%
H
11.1
12.5
|
L
 19.6%
H
8.6
12.5
|
L
 -1.6%
H
8.6
14.3
|
L
 -8.4%
H
7.7
15.2
|
L
 -81.0%
H
7.7
120.2
|
L
 -69.9%
H
7.7
120.2
|
L
 -98.8%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,351.2
|
3.7
|
L
 -3.1%
H
3.7
3.9
|
L
 -6.3%
H
3.7
4.2
|
L
 -7%
H
3.5
4.2
|
L
 -36.5%
H
3.5
5.9
|
L
 148%
H
1.2
6.8
|
L
 107.8%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| ETHZilla Corp |
|
86.5
|
4.6
|
L
 -1.9%
H
4.5
4.7
|
L
 -13.7%
H
4.5
5.3
|
L
 -11.5%
H
4.5
5.7
|
L
 -78.0%
H
4.5
21.3
|
L
 -67.7%
H
4.5
174.6
|
L
 -99.3%
H
4.5
834.1
|
L
 -100.0%
H
4.5
49571
|
L
H
4.5
49571
|
| Atossa Therapeutics Inc |
|
73.6
|
0.6
|
L
 -5%
H
0.6
0.6
|
L
 -13.6%
H
0.6
0.7
|
L
 -13.6%
H
0.6
0.7
|
L
 -35.2%
H
0.6
1.0
|
L
 -32.9%
H
0.6
1.3
|
L
 -30.5%
H
0.6
2.3
|
L
 -74.2%
H
0.5
9.8
|
L
 -98.8%
H
0.5
127.8
|
| Atara Biotherapeutics Inc |
|
38.5
|
5.3
|
L
 -3.1%
H
5.2
5.6
|
L
 6.8%
H
4.9
5.7
|
L
 -70.3%
H
4.2
19.1
|
L
 -62.0%
H
4.2
19.1
|
L
 -34.0%
H
4.2
19.1
|
L
 -95.9%
H
0.4
141
|
L
 -98.8%
H
0.4
546.3
|
L
 -98.8%
H
0.4
1361.3
|
| Atea Pharma Inc |
|
307.8
|
3.9
|
L
 0.8%
H
3.8
4.1
|
L
 8.0%
H
3.6
4.3
|
L
 9.4%
H
3.3
4.3
|
L
 19.8%
H
2.9
4.3
|
L
 31.3%
H
2.5
4.3
|
L
 -14.3%
H
2.5
5.2
|
L
 -94.6%
H
2.5
94.2
|
L
H
2.5
94.2
|
| Avalo Therapeutics Inc |
|
275.8
|
14.9
|
L
 -2.3%
H
14.8
15.4
|
L
 -8.3%
H
14.5
16.5
|
L
 -19.7%
H
14.5
18.5
|
L
 -17.4%
H
14.0
20.7
|
L
 96.1%
H
3.4
20.7
|
L
 272.5%
H
0.0
34.5
|
L
 -60.6%
H
0.0
54
|
L
 -60.5%
H
0.0
91.8
|
| Aytu BioPharma Inc |
|
26.5
|
2.6
|
L
 0.8%
H
2.6
2.7
|
L
 -4.1%
H
2.5
2.8
|
L
 2.4%
H
2.5
3.1
|
L
 19.3%
H
1.8
3.1
|
L
 62.5%
H
1.0
3.1
|
L
 -21.5%
H
1.0
3.5
|
L
 -98.2%
H
1.0
235.3
|
L
 -100.0%
H
1.0
950400
|
| Adagene Inc (ADR) |
|
132.9
|
2.8
|
L
 -3.1%
H
2.8
2.9
|
L
 38.9%
H
2
2.9
|
L
 57.5%
H
1.5
2.9
|
L
 53.3%
H
1.3
2.9
|
L
 52.4%
H
1.3
3.2
|
L
 44.6%
H
1.1
4.4
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
10.2
|
8.2
|
L
H
7.8
8.2
|
L
 3%
H
7.6
8.5
|
L
 7.3%
H
7
10.4
|
L
 -13.0%
H
7
10.4
|
L
 9.0%
H
6.5
12.1
|
L
 -61.1%
H
5
45.6
|
L
 -96.2%
H
5
252.9
|
L
H
5
750.4
|
| Amarin Corp (ADR) |
|
311.5
|
15.0
|
L
 -2.9%
H
15.0
15.5
|
L
 -9.3%
H
14.7
17.3
|
L
 6.7%
H
13.1
17.3
|
L
 -10.9%
H
13.1
17.3
|
L
 2575%
H
0.4
20.9
|
L
 709.7%
H
0.4
20.9
|
L
 99.7%
H
0.4
20.9
|
L
 1001.5%
H
0.4
26.1
|
| Ascendis Pharma A/S (ADR) |
|
13,621.8
|
223.0
|
L
 -0.5%
H
221.5
228.5
|
L
 -2.5%
H
220.5
242
|
L
 5.7%
H
188.1
242
|
L
 8.4%
H
188.1
242
|
L
 74.8%
H
118.0
242
|
L
 82%
H
64.3
242
|
L
 48.5%
H
61.6
242
|
L
 1071.0%
H
11.9
242
|
| Alterity Therapeutics Ltd (ADR) |
|
58.5
|
3.2
|
L
 -0.9%
H
3.2
3.2
|
L
 -1.2%
H
3.2
3.8
|
L
 7.0%
H
3.0
3.8
|
L
 -31.3%
H
2.7
4.6
|
L
 11%
H
2.5
7
|
L
 -17.4%
H
1
7
|
L
 -80.4%
H
1
27.5
|
L
 -89.8%
H
1
66.9
|
| Avadel Pharma PLC (ADR) |
|
2,117.1
|
21.6
|
L
 0.1%
H
21.5
21.6
|
L
 0.2%
H
21.5
21.7
|
L
 0.1%
H
21.4
21.7
|
L
 14.1%
H
18.7
23.6
|
L
 181.6%
H
6.4
23.6
|
L
 192.3%
H
6.4
23.6
|
L
 195.5%
H
1.1
23.6
|
L
 112.3%
H
1.0
23.6
|
| Astrazeneca PLC (ADR) |
|
288,104.7
|
92.9
|
L
 0.4%
H
92.8
93.4
|
L
 1.3%
H
91.4
96.2
|
L
 0.4%
H
89.0
96.5
|
L
 13%
H
80.5
96.5
|
L
 32.3%
H
61.2
96.5
|
L
 41.8%
H
60.5
96.5
|
L
 83.6%
H
46.5
96.5
|
L
 188.4%
H
25.6
96.5
|
| Biofrontera Inc |
|
11.2
|
1.0
|
L
 -3.0%
H
1.0
1.0
|
L
 -4%
H
1.0
1.0
|
L
 31.5%
H
0.6
1.0
|
L
 -9.4%
H
0.6
1.2
|
L
 -8.6%
H
0.5
1.2
|
L
 -94.8%
H
0.5
19.2
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biomea Fusion Inc |
|
82.7
|
1.2
|
L
 -0.9%
H
1.2
1.2
|
L
 -18.2%
H
1.2
1.4
|
L
 -3.3%
H
1.2
1.7
|
L
 -14.6%
H
0.9
1.7
|
L
 -72.3%
H
0.9
4.4
|
L
 -87.3%
H
0.9
43.7
|
L
H
0.9
43.7
|
L
H
0.9
43.7
|
| Bolt Biotherapeutics Inc |
|
11.7
|
6.1
|
L
 -2.1%
H
6
6.3
|
L
 -2.1%
H
6
7.1
|
L
 13.8%
H
5.2
7.2
|
L
 4.4%
H
4.4
7.2
|
L
 -38.6%
H
4.4
10.5
|
L
 -79.2%
H
4.4
40.6
|
L
H
4.4
861.4
|
L
H
4.4
861.4
|
| Blue Water Biotech Inc |
|
26.6
|
1.5
|
L
 -0.7%
H
1.5
1.5
|
L
 -8.6%
H
1.4
1.7
|
L
 3.5%
H
1.4
2.3
|
L
 -58.6%
H
1.4
4
|
L
 1762.5%
H
0.1
5.9
|
L
 15.5%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
63.7
|
1.6
|
L
 -0.6%
H
1.6
1.6
|
L
 -7.2%
H
1.5
1.7
|
L
 -14.8%
H
1.4
1.8
|
L
 -15.3%
H
1.4
2.4
|
L
 -10.4%
H
1.0
3.4
|
L
 -38.7%
H
0.7
4
|
L
 -87.2%
H
0.5
33
|
L
H
0.5
48.5
|
| Biodexa Pharma PLC (ADR) |
|
1.5
|
1.8
|
L
 -3.3%
H
1.7
1.8
|
L
 -18.0%
H
1.7
2.3
|
L
 -23.3%
H
1.7
2.6
|
L
 -70.0%
H
1.7
8.9
|
L
 -95.8%
H
1.7
92
|
L
 -100.0%
H
1.7
1680000
|
L
 -100.0%
H
1.7
38295000
|
L
 -100.0%
H
1.7
2720000000
|
| BeiGene Ltd (ADR) |
|
37,284.2
|
350
|
L
H
345.5
353
|
L
 3.3%
H
334.4
353
|
L
 12.8%
H
302.1
353.1
|
L
 11.2%
H
299.5
385.2
|
L
 53.3%
H
228.9
385.2
|
L
 34.7%
H
127.0
385.2
|
L
 9.4%
H
118.2
426.6
|
L
H
22.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
13.8
|
3.2
|
L
H
3.0
3.2
|
L
 7.1%
H
2.9
3.2
|
L
 8.6%
H
2.7
3.2
|
L
 -9.4%
H
2.7
3.9
|
L
 -24.9%
H
2.3
7.8
|
L
 -87.6%
H
0.1
101.2
|
L
 -97.2%
H
0.1
253.6
|
L
 -99.5%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,303.6
|
168.0
|
L
 -0.6%
H
166.6
169.3
|
L
 5.1%
H
156.5
174.8
|
L
 1.7%
H
146.1
174.8
|
L
 71.5%
H
95.3
174.8
|
L
 192.7%
H
49
174.8
|
L
 461.0%
H
11
174.8
|
L
H
6
174.8
|
L
H
6
174.8
|
| Neuphoria Therapeutics Inc |
|
21.7
|
4.0
|
L
 0.3%
H
4
4.0
|
L
 -3.4%
H
4.0
4.3
|
L
 6.9%
H
3.7
4.4
|
L
 -12.0%
H
3.6
5.2
|
L
 -22.7%
H
3.6
21.4
|
L
 -5.8%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| Capricor Therapeutics Inc |
|
1,223.4
|
22.5
|
L
 -0.5%
H
22.2
23
|
L
 -7.0%
H
21.1
24.1
|
L
 -25.1%
H
21.1
30.1
|
L
 225%
H
4.3
40.4
|
L
 57.6%
H
4.3
40.4
|
L
 430.4%
H
2.7
40.4
|
L
 241.8%
H
2.6
40.4
|
L
 -15.8%
H
0.9
54
|
| CASI Pharma Inc |
|
21.2
|
1.0
|
L
 4.0%
H
1.0
1.0
|
L
 4.0%
H
0.9
1.0
|
L
 33.8%
H
0.8
1.2
|
L
 -27.5%
H
0.8
1.5
|
L
 -56.4%
H
0.8
3.1
|
L
 -49.5%
H
0.8
8.5
|
L
 -96.9%
H
0.8
36.8
|
L
 -90.5%
H
0.8
88.9
|
| Cullinan Oncology Inc |
|
700.6
|
11.9
|
L
 -0.5%
H
11.6
12.3
|
L
 -5.7%
H
11.5
12.9
|
L
 17.0%
H
9.4
13.0
|
L
 54.2%
H
6.7
13.3
|
L
 5.4%
H
5.7
13.3
|
L
 3.4%
H
5.7
30.2
|
L
 -68.8%
H
5.7
59.9
|
L
H
5.7
59.9
|
| Coherus Biosciences Inc |
|
272.0
|
2.3
|
L
 -3.4%
H
2.2
2.4
|
L
 41.5%
H
1.8
2.6
|
L
 67.9%
H
1.4
2.6
|
L
 30.1%
H
1.1
2.6
|
L
 84.4%
H
0.7
2.6
|
L
 -73.0%
H
0.7
9.1
|
L
 -88.0%
H
0.7
21.6
|
L
 -83.0%
H
0.7
32.0
|
| Cingulate Inc |
|
41.7
|
5.6
|
L
 -2.1%
H
5.6
5.9
|
L
 4.3%
H
4.8
6.7
|
L
 37.3%
H
4.1
6.7
|
L
 57.3%
H
3.2
6.7
|
L
 18.1%
H
3.2
6.7
|
L
 489.5%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
49.1
|
4.2
|
L
H
4.1
4.4
|
L
 -23.1%
H
4.1
5.4
|
L
 -29.2%
H
4.1
6.7
|
L
 -54.4%
H
4.1
13.5
|
L
 -12.0%
H
2.3
13.5
|
L
 -85.8%
H
2.3
39.8
|
L
 -96.7%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
13.9
|
3.3
|
L
 0.9%
H
3.2
3.4
|
L
 -14.2%
H
3.2
3.9
|
L
 27.7%
H
2.6
4.1
|
L
 -2.4%
H
2.5
4.1
|
L
 -55.1%
H
2.5
20.6
|
L
 -92.9%
H
2.5
133.5
|
L
 -99.4%
H
2.5
894
|
L
 -100.0%
H
2.5
22200
|
| Clearmind Medicine Inc |
|
3.3
|
2.2
|
L
 0.5%
H
2.2
2.4
|
L
 -18.5%
H
2.1
2.8
|
L
 12.8%
H
1.7
2.8
|
L
 -94.5%
H
1.7
38.9
|
L
 -96.0%
H
1.7
60
|
L
 -100.0%
H
1.7
6050.4
|
L
 -100.0%
H
1.7
788400
|
L
H
1.7
788400
|
| Compass Therapeutics Inc |
|
1,117.0
|
6.3
|
L
 -1.6%
H
6.2
6.5
|
L
 0.2%
H
5.7
6.5
|
L
 21.9%
H
4.8
6.5
|
L
 66.1%
H
3.5
6.5
|
L
 101.9%
H
1.3
6.5
|
L
 59.4%
H
0.8
6.5
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
3.4
|
5.5
|
L
 -4.8%
H
5.5
5.5
|
L
 -11.8%
H
5.5
6.5
|
L
 3.8%
H
5.2
8.9
|
L
 -27.5%
H
5.2
8.9
|
L
 -99.8%
H
4.9
5700
|
L
 -100.0%
H
4.9
6600000
|
L
 -100.0%
H
4.9
200700000
|
L
H
4.9
256050000
|
| Context Therapeutics Inc |
|
241.6
|
2.6
|
L
 6.5%
H
2.4
2.7
|
L
 46.9%
H
1.7
2.7
|
L
 117.4%
H
1.2
2.7
|
L
 128.7%
H
1
2.7
|
L
 220.7%
H
0.5
2.7
|
L
 275.7%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
13.8
|
1
|
L
H
1
1
|
L
 -5.7%
H
1.0
1.1
|
L
 2.0%
H
0.9
1.2
|
L
 -6.5%
H
0.9
1.2
|
L
 -50%
H
0.9
2.7
|
L
 -63.1%
H
0.9
3.3
|
L
 -95.2%
H
0.9
41.5
|
L
 -99.5%
H
0.9
309.6
|
| Collegium pharma Inc |
|
1,424.4
|
45.1
|
L
 -0.6%
H
45.0
45.7
|
L
 -4.3%
H
43.6
47.4
|
L
 -8.9%
H
43.6
49.5
|
L
 29.5%
H
33.9
50.8
|
L
 39.0%
H
23.2
50.8
|
L
 59.3%
H
20.8
50.8
|
L
 86.7%
H
14.0
50.8
|
L
 164.6%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
4,144.4
|
39.4
|
L
 -11.7%
H
36.8
39.7
|
L
 -4.6%
H
36.8
47.1
|
L
 -50.6%
H
33.0
79.8
|
L
 -45.3%
H
33.0
89
|
L
 -36.0%
H
33.0
117.3
|
L
 69.4%
H
17.9
117.3
|
L
 39.4%
H
15.8
117.3
|
L
 979.5%
H
3.3
117.3
|
| Cosmos Health Inc |
|
17.6
|
0.5
|
L
H
0.5
0.5
|
L
 -7.8%
H
0.4
0.5
|
L
 -4.1%
H
0.4
0.6
|
L
 -49.5%
H
0.4
1.0
|
L
 -35.6%
H
0.3
1.3
|
L
 -92.8%
H
0.3
7.3
|
L
 -99.6%
H
0.3
225
|
L
 -99.6%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
58.0
|
3.9
|
L
 4.9%
H
3.6
4.0
|
L
 -4.0%
H
3.6
4.2
|
L
 -4.7%
H
3.6
5.4
|
L
 19.4%
H
1.9
5.4
|
L
 73.2%
H
1.9
7.3
|
L
 42.1%
H
1.0
7.3
|
L
 22.4%
H
1.0
7.5
|
L
 -21.8%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
2,983.1
|
24.3
|
L
 -1.3%
H
24.1
24.8
|
L
 -0.7%
H
23.6
24.8
|
L
 0.9%
H
22.1
24.8
|
L
 15.5%
H
20.7
25.1
|
L
 1.3%
H
19.1
26.6
|
L
 56.4%
H
11.1
26.6
|
L
 566.8%
H
3.3
26.6
|
L
 1204.8%
H
0.5
26.6
|
| Corbus Pharma Holdings Inc |
|
146.0
|
8.3
|
L
 -3.6%
H
8.3
8.7
|
L
 -6.1%
H
8.3
9.6
|
L
 1.1%
H
7.6
9.6
|
L
 -50.7%
H
7.6
17.2
|
L
 -13.5%
H
4.6
20.6
|
L
 91.7%
H
2.1
61.9
|
L
 -84.8%
H
2.1
120
|
L
 -80.3%
H
2.1
323.4
|
| Crinetics Pharma Inc |
|
5,270.1
|
51.4
|
L
 -0.9%
H
51.0
53.0
|
L
 -6.4%
H
50.8
55.3
|
L
 8.2%
H
43.4
58.0
|
L
 19.8%
H
38.8
58.0
|
L
 30.6%
H
24.1
58.0
|
L
 152.0%
H
15.2
62.5
|
L
 258.3%
H
13.8
62.5
|
L
H
10.6
62.5
|
| Corvus Pharma Inc |
|
1,743.2
|
20.8
|
L
 -0.6%
H
20.6
21.7
|
L
 -18.5%
H
20.3
27.0
|
L
 179.3%
H
6.4
27.0
|
L
 171.0%
H
6.4
27.0
|
L
 309.7%
H
2.5
27.0
|
L
 2407.2%
H
0.6
27.0
|
L
 459.4%
H
0.6
27.0
|
L
H
0.6
27.0
|
| CytomX Therapeutics Inc |
|
926.8
|
5.5
|
L
 -4.7%
H
5.4
5.9
|
L
 -4.4%
H
5.3
6.1
|
L
 30.6%
H
4.0
6.2
|
L
 67.8%
H
3.2
6.2
|
L
 567.1%
H
0.4
6.2
|
L
 97.5%
H
0.4
6.2
|
L
 -20.8%
H
0.4
10.1
|
L
 -65.2%
H
0.4
35
|
| Cyclacel Pharma Inc |
|
6.0
|
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 -12.2%
H
1.2
1.5
|
L
 -15.9%
H
1.2
1.7
|
L
 -32.2%
H
1.2
2.0
|
L
 -98.6%
H
1.2
100.8
|
L
 -100.0%
H
1.2
4212
|
L
 -100.0%
H
1.2
41112
|
L
 -100.0%
H
1.2
784800
|
| Cyclerion Therapeutics Inc |
|
5.1
|
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -2.2%
H
1.3
1.7
|
L
 12.5%
H
1.2
2.3
|
L
 -31.5%
H
1.2
2.3
|
L
 -43.0%
H
1.2
6.3
|
L
 -89.9%
H
1.2
19.1
|
L
 -97.9%
H
1.2
138
|
L
H
1.2
457
|
| Cytokinetics Inc |
|
7,820.1
|
64.0
|
L
 -2.5%
H
63.6
65.7
|
L
 -1.5%
H
62.1
66.0
|
L
 3.6%
H
58.9
66.6
|
L
 3.2%
H
58.1
71.0
|
L
 31.5%
H
29.3
71.0
|
L
 48.3%
H
26.0
110
|
L
 225.2%
H
17.7
110
|
L
 730.6%
H
5.8
110
|
| Cellectis (ADR) |
|
389.3
|
3.9
|
L
 -2.8%
H
3.9
3.9
|
L
 -11.2%
H
3.8
4.5
|
L
 -21.8%
H
3.8
5
|
L
 6.9%
H
3.1
5.5
|
L
 155.3%
H
1.1
5.5
|
L
 25.2%
H
1.0
5.5
|
L
 -85.8%
H
1.0
30.1
|
L
 -82.6%
H
1.0
38.9
|
| Centessa Pharma PLC (ADR) |
|
3,609.8
|
24.4
|
L
 -1.9%
H
23.9
25.2
|
L
 -0.9%
H
23.9
26.6
|
L
 -1.5%
H
21.5
26.6
|
L
 1.8%
H
17.1
30.6
|
L
 44.0%
H
9.6
30.6
|
L
 546.0%
H
3
30.6
|
L
H
2.9
30.6
|
L
H
2.9
30.6
|
| Connect Biopharma Holdings Ltd (ADR) |
|
139.9
|
2.5
|
L
 -1.6%
H
2.5
2.5
|
L
 -5.6%
H
2.3
2.7
|
L
 -6.3%
H
2.0
2.9
|
L
 58.9%
H
1.5
3.3
|
L
 158.8%
H
0.5
3.3
|
L
 96.1%
H
0.5
3.3
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
27.1
|
1.9
|
L
H
1.9
1.9
|
L
 -3.6%
H
1.9
2
|
L
 -5%
H
1.9
2.1
|
L
 -5.9%
H
1.6
2.5
|
L
 -41.2%
H
1.6
9.2
|
L
 -88.3%
H
0.3
16.1
|
L
 -93.0%
H
0.3
31.0
|
L
 -99.3%
H
0.3
519.6
|
| Day One Biopharma Inc |
|
1,144.8
|
11.2
|
L
 -0.1%
H
11.2
11.5
|
L
 -9.6%
H
11.1
12.9
|
L
 19%
H
8.4
13.2
|
L
 58.4%
H
6.9
13.2
|
L
 -14.3%
H
5.6
13.2
|
L
 -48.0%
H
5.6
22.1
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
281.4
|
8.5
|
L
 0.1%
H
8.4
8.6
|
L
 -8.6%
H
8.0
9.6
|
L
 9.7%
H
7.0
9.6
|
L
 6.6%
H
7.0
9.6
|
L
 114.7%
H
3.9
9.6
|
L
 323%
H
1.0
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
5.2
|
L
 -4.3%
H
5.1
5.4
|
L
 -21.4%
H
5.1
6.6
|
L
 -33.9%
H
5.1
8.3
|
L
 -24.9%
H
5.1
10
|
L
 -41.1%
H
5.1
13.1
|
L
 -44.3%
H
4.1
14.4
|
L
 -94.0%
H
4.1
138.8
|
L
 -100.0%
H
4.1
17437.5
|
| DiaMedica Therapeutics Inc |
|
427.0
|
8.2
|
L
 -3.2%
H
8.2
8.6
|
L
 -1.6%
H
8.0
9
|
L
 -1.0%
H
7.2
9
|
L
 22.6%
H
5.3
10.4
|
L
 39.2%
H
3.2
10.4
|
L
 457.8%
H
1.3
10.4
|
L
 2.1%
H
1.1
10.9
|
L
 276.1%
H
1.1
13.8
|
| Dermata Therapeutics Inc |
|
7.5
|
2.7
|
L
 -5.3%
H
2.7
2.9
|
L
 10.4%
H
2.2
4.7
|
L
 43.0%
H
1.8
4.7
|
L
 -28.1%
H
1.6
4.7
|
L
 119.8%
H
0.6
7.1
|
L
 -49.6%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| DBV Tech (ADR) |
|
1,249.3
|
23.0
|
L
 0.2%
H
22.9
23.5
|
L
 -0.1%
H
22.7
25.4
|
L
 17.9%
H
16.5
25.4
|
L
 51.3%
H
12.6
26.2
|
L
 445.3%
H
3.8
26.2
|
L
 66.7%
H
0.5
26.2
|
L
 -55.2%
H
0.5
68.8
|
L
 -91.1%
H
0.5
505.7
|
| Edesa Biotech Inc |
|
10.2
|
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 -17.6%
H
1.2
1.5
|
L
 -17.6%
H
1.2
1.6
|
L
 -41.1%
H
1.2
2.0
|
L
 -33.3%
H
1.2
4.5
|
L
 -88.2%
H
1.2
11.2
|
L
 -97.0%
H
1.2
84
|
L
 -99.9%
H
1.2
2037.4
|
| Eledon Pharma Inc |
|
174.4
|
2.2
|
L
 1.9%
H
2.1
2.2
|
L
 -1.8%
H
2.1
2.3
|
L
 41.3%
H
1.4
2.3
|
L
 -48.5%
H
1.4
4.6
|
L
 -53.8%
H
1.4
5.0
|
L
 -33.4%
H
1.1
5.4
|
L
 -85.2%
H
1.1
22.9
|
L
 -99.8%
H
1.1
1425.6
|
| Enanta Pharma Inc |
|
368.0
|
12.7
|
L
 -1.7%
H
12.5
13.0
|
L
 -0.9%
H
12.3
13.3
|
L
 -22.8%
H
12.1
16.9
|
L
 19.3%
H
10.2
17.2
|
L
 154.6%
H
4.1
17.2
|
L
 -75.6%
H
4.1
62.1
|
L
 -73.6%
H
4.1
102
|
L
 -50.7%
H
4.1
127.8
|
| Entera Bio Ltd |
|
66.5
|
1.5
|
L
 -0.7%
H
1.4
1.5
|
L
 -8.2%
H
1.4
1.6
|
L
 -19.4%
H
1.4
2.0
|
L
 -46.9%
H
1.4
3.2
|
L
 -39.1%
H
1.4
3.2
|
L
 61.1%
H
0.5
3.4
|
L
 -0.7%
H
0.5
10.2
|
L
H
0.5
10.2
|
| Evolus Inc |
|
300.8
|
4.6
|
L
 -0.4%
H
4.6
4.8
|
L
 -8.7%
H
4.6
5.1
|
L
 -30.3%
H
4.6
6.8
|
L
 -32.4%
H
4.6
7.8
|
L
 -68.1%
H
4.6
17.1
|
L
 -54.7%
H
4.6
17.8
|
L
 -31.4%
H
4.6
17.8
|
L
H
2.9
39.5
|
| Erasca Inc |
|
3,170.2
|
10.2
|
L
 -0.7%
H
10.2
10.4
|
L
 -0.5%
H
9.1
10.7
|
L
 196.0%
H
3.4
10.7
|
L
 333.9%
H
2.1
10.7
|
L
 456.5%
H
1.0
10.7
|
L
 153.5%
H
1.0
10.7
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
803.7
|
3.4
|
L
 -4.5%
H
3.4
3.6
|
L
 6.9%
H
3.1
3.6
|
L
 -12.9%
H
2.9
4.2
|
L
 18.1%
H
2.4
4.2
|
L
 79.4%
H
0.7
4.2
|
L
 -49.3%
H
0.7
6.7
|
L
 -89.2%
H
0.7
36.9
|
L
 -77.2%
H
0.7
82.7
|
| Eton Pharma Inc |
|
406.0
|
15.1
|
L
 -0.7%
H
15.1
15.4
|
L
 -0.9%
H
14.6
15.4
|
L
 -9.9%
H
14.6
17.2
|
L
 -17.3%
H
14.6
20.0
|
L
 -11.3%
H
11.1
23
|
L
 321.7%
H
2.4
23
|
L
 69.7%
H
2.0
23
|
L
H
2.0
23
|
| Exelixis Inc |
|
10,995.3
|
41.0
|
L
 -3%
H
40.8
42.5
|
L
 -7.8%
H
40.8
45.4
|
L
 -9.6%
H
40.8
46.3
|
L
 4.0%
H
36
47.2
|
L
 24.4%
H
32.4
49.6
|
L
 134.7%
H
16.2
49.6
|
L
 84.6%
H
14.9
49.6
|
L
 787.7%
H
3.6
49.6
|
| Hyperion DeFi Inc |
|
28.8
|
3.5
|
L
 -3.6%
H
3.5
3.6
|
L
 20.9%
H
2.8
4.0
|
L
 0.9%
H
2.8
4.1
|
L
 -51.0%
H
2.8
7.5
|
L
 18.5%
H
0.0
17.2
|
L
 -97.9%
H
0.0
468
|
L
 -99.3%
H
0.0
617.6
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,168.1
|
14.1
|
L
 -4.3%
H
14
14.9
|
L
 -13.7%
H
14
16.7
|
L
 -22.5%
H
14
18.5
|
L
 20.3%
H
9.7
19.1
|
L
 82.5%
H
3.9
19.1
|
L
 198.3%
H
2.2
31.0
|
L
 26.0%
H
2.2
31.0
|
L
 -58.6%
H
2.2
42.5
|
| Evotec SE (ADR) |
|
1,303.6
|
3.7
|
L
 -2.9%
H
3.7
3.7
|
L
 2.2%
H
3.5
3.8
|
L
 16.5%
H
3.1
3.9
|
L
 -11.6%
H
2.9
4.1
|
L
 -13.0%
H
2.8
4.8
|
L
 -63.9%
H
2.8
13.5
|
L
 -81.4%
H
2.8
26.6
|
L
 105.0%
H
1.6
26.6
|
| Fortress Biotech Inc |
|
101.2
|
3.3
|
L
 -3.0%
H
3.3
3.4
|
L
 -6.3%
H
3.3
3.5
|
L
 -8.9%
H
3.3
4.5
|
L
 29.4%
H
2.4
4.5
|
L
 87.4%
H
1.3
4.5
|
L
 -76.6%
H
1.2
14.3
|
L
 -93.2%
H
1.2
91.5
|
L
 -91.2%
H
1.2
91.5
|
| Fennec Pharma Inc |
|
254.8
|
7.5
|
L
 -0.8%
H
7.4
7.6
|
L
 -4.4%
H
7.4
8.0
|
L
 -3.0%
H
7.4
8.1
|
L
 -11.9%
H
7.4
9
|
L
 15.3%
H
4.7
9.9
|
L
 -21.1%
H
4.0
11.9
|
L
 3.6%
H
3.8
11.9
|
L
 262.1%
H
1.4
15.0
|
| Kyntra Bio Inc |
|
32.6
|
8.1
|
L
 0.8%
H
8.1
8.1
|
L
 -10.0%
H
8.0
9.1
|
L
 -8.1%
H
8.0
9.8
|
L
 -26.0%
H
8.0
11.4
|
L
 -32.8%
H
4.9
22.0
|
L
 -98.5%
H
4.5
642.3
|
L
 -99.3%
H
4.5
1430.2
|
L
 -98.4%
H
4.5
1713.8
|
| Q32 Bio Inc |
|
48.5
|
3.9
|
L
 -2.0%
H
3.9
4.1
|
L
 -3.9%
H
3.7
4.2
|
L
 23.1%
H
3.1
4.2
|
L
 47.0%
H
1.9
6.4
|
L
 22.4%
H
1.3
6.4
|
L
 -85.4%
H
1.3
53.8
|
L
 -98.2%
H
1.3
274.3
|
L
H
1.3
572.4
|
| Amicus Therapeutics Inc |
|
4,479.7
|
14.3
|
L
 0.1%
H
14.3
14.3
|
L
 0.1%
H
14.3
14.3
|
L
 0.2%
H
14.2
14.4
|
L
 60.5%
H
8.6
14.4
|
L
 48.9%
H
5.5
14.4
|
L
 11.3%
H
5.5
14.6
|
L
 -24.5%
H
5.5
21.1
|
L
 136.4%
H
4.4
25.4
|
| Fulcrum Therapeutics Inc |
|
707.9
|
10.7
|
L
 -1.9%
H
10.7
11.1
|
L
 -2.9%
H
10.4
11.3
|
L
 -10.5%
H
9.1
12.3
|
L
 14.6%
H
7.3
15.7
|
L
 163.0%
H
2.3
15.7
|
L
 -16.6%
H
2.3
15.7
|
L
 -3.0%
H
2.3
33.1
|
L
H
2.3
33.1
|
| Generation Bio Co |
|
37.6
|
5.6
|
L
 -0.5%
H
5.6
5.6
|
L
 -1.9%
H
5.5
5.7
|
L
 -1.1%
H
5.3
5.8
|
L
 0.2%
H
4.9
5.9
|
L
 -35.1%
H
3
8.7
|
L
 -90.9%
H
3
73.5
|
L
 -97.9%
H
3
418.6
|
L
H
3
557.2
|
| GH Research PLC |
|
1,022.2
|
16.5
|
L
 1.5%
H
16.0
16.5
|
L
 -1.6%
H
15.5
17.0
|
L
 30.8%
H
12.4
19
|
L
 19.7%
H
12.0
19
|
L
 74.8%
H
8.0
20.5
|
L
 72.9%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Galmed Pharma Ltd |
|
4.0
|
0.7
|
L
 -2.7%
H
0.7
0.7
|
L
 -14.1%
H
0.7
0.9
|
L
 -7.6%
H
0.7
0.9
|
L
 -45.9%
H
0.7
1.5
|
L
 -74.1%
H
0.7
3.5
|
L
 -99.4%
H
0.2
147.4
|
L
 -99.9%
H
0.2
1125
|
L
 -99.9%
H
0.2
4870.8
|
| Galecto Inc |
|
40.7
|
25.5
|
L
 1.4%
H
24
25.5
|
L
 -14.0%
H
23.9
28.3
|
L
 -14.1%
H
19.4
32
|
L
 240.7%
H
5.0
38.3
|
L
 399.0%
H
2.0
38.3
|
L
 1056.8%
H
0.5
38.3
|
L
 105.4%
H
0.5
38.3
|
L
H
0.5
38.3
|
| GlycoMimetics Inc |
|
654.4
|
10.1
|
L
 -5.5%
H
10
11.2
|
L
 -25.6%
H
10
14.0
|
L
 -16.1%
H
10
14.7
|
L
 -18.9%
H
10
16.4
|
L
 -59.9%
H
9.8
37
|
L
 -97.0%
H
9.8
416
|
L
 -97.2%
H
9.8
440
|
L
 -97.8%
H
9.8
2605
|
| Genelux Corp |
|
119.8
|
2.7
|
L
 -2.2%
H
2.7
2.8
|
L
 -6.9%
H
2.7
3.0
|
L
 -38.8%
H
2.5
5.0
|
L
 -65.2%
H
2.5
8.5
|
L
 -34.3%
H
2.0
8.5
|
L
 -55.4%
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
5.8
|
2.6
|
L
 4.5%
H
2.5
2.9
|
L
 -12.3%
H
2.1
3.1
|
L
 46.0%
H
1.7
3.6
|
L
 -61.3%
H
1.7
6.8
|
L
 314.5%
H
0.1
13.0
|
L
 91.8%
H
0.1
13.0
|
L
 -42.5%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
543.9
|
2.4
|
L
 -2.9%
H
2.3
2.5
|
L
 -18.1%
H
2.3
2.9
|
L
 -26.8%
H
2.3
3.3
|
L
 -1.7%
H
2.2
3.9
|
L
 155.4%
H
0.8
3.9
|
L
 -3.3%
H
0.5
3.9
|
L
 -76.7%
H
0.5
15.2
|
L
H
0.5
27.2
|
| GT Biopharma Inc |
|
18.1
|
0.7
|
L
H
0.7
0.7
|
L
 -5.6%
H
0.7
0.7
|
L
 -26.1%
H
0.6
0.9
|
L
 13.3%
H
0.5
1.2
|
L
 -67.8%
H
0.5
3.9
|
L
 -20%
H
0.2
10.7
|
L
 -91.5%
H
0.2
19.7
|
L
 -100.0%
H
0.2
12240
|
| Genmab (ADR) |
|
20,167.6
|
32.7
|
L
 -1.8%
H
32.7
33.2
|
L
 -1.1%
H
32.6
34.7
|
L
 0.7%
H
30.4
35.4
|
L
 13.1%
H
28.1
35.4
|
L
 64.9%
H
17.2
35.4
|
L
 -15.8%
H
17.2
43
|
L
 -17.5%
H
17.2
49.1
|
L
 162.1%
H
9.2
49.1
|
| Genenta Science SpA (ADR) |
|
25.8
|
1.1
|
L
 -6.0%
H
1.1
1.2
|
L
 -17.9%
H
1.1
1.7
|
L
 -21.4%
H
1.1
1.7
|
L
 -63.5%
H
1.1
3.2
|
L
 -72.6%
H
1.1
10
|
L
 -81.0%
H
1.1
10
|
L
H
1.1
13.1
|
L
H
1.1
13.1
|
| Grifols SA (ADR) - Level III |
|
6,260.7
|
9.2
|
L
 -1.0%
H
9.2
9.3
|
L
 1.0%
H
9.0
9.4
|
L
 0.9%
H
8.6
9.6
|
L
 -2.0%
H
7.6
9.9
|
L
 31.4%
H
6.2
11.1
|
L
 -0.3%
H
5.3
12.2
|
L
 -48.0%
H
5.3
19.1
|
L
 -36.6%
H
5.3
25.7
|
| Hoth Therapeutics Inc |
|
14.3
|
0.9
|
L
H
0.9
0.9
|
L
 -12.4%
H
0.9
1.1
|
L
 -8.9%
H
0.9
1.1
|
L
 -34.3%
H
0.9
1.5
|
L
 -25.8%
H
0.7
2.1
|
L
 -80.8%
H
0.6
5.4
|
L
 -98.3%
H
0.6
87.5
|
L
H
0.6
347
|
| Werewolf Therapeutics Inc |
|
34.5
|
0.7
|
L
 -1.4%
H
0.7
0.8
|
L
 1.4%
H
0.6
0.8
|
L
 14.5%
H
0.5
0.8
|
L
 -54.5%
H
0.5
1.6
|
L
 -47.0%
H
0.5
2.4
|
L
 -82.7%
H
0.5
8.2
|
L
H
0.5
24.0
|
L
H
0.5
24.0
|
| Harmony Biosciences Holdings Inc |
|
2,091.9
|
36.3
|
L
 -1.5%
H
36.2
37.2
|
L
 -1.2%
H
36.2
38.0
|
L
 -4.2%
H
34.7
39.4
|
L
 23.9%
H
27.7
40.9
|
L
 -6.4%
H
25.5
40.9
|
L
 -25.2%
H
18.6
50.8
|
L
 1.3%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,529.6
|
41.3
|
L
 -1.5%
H
41.3
42.4
|
L
 -8.9%
H
41.3
45.4
|
L
 -18.6%
H
41.3
54.9
|
L
 12.3%
H
32.6
54.9
|
L
 27.7%
H
20.9
54.9
|
L
 180.4%
H
7.6
59.2
|
L
 358.9%
H
5.4
59.2
|
L
 593.0%
H
1.4
59.2
|
| HUTCHMED (China) Ltd (ADR) |
|
2,612.9
|
15.2
|
L
 -0.3%
H
15.2
15.2
|
L
 -1.6%
H
15
15.8
|
L
 13.4%
H
13.1
16.3
|
L
 3.3%
H
13.1
16.3
|
L
 11.4%
H
11.5
19.5
|
L
 -23.5%
H
10.7
21.9
|
L
 -52.4%
H
7.4
43.9
|
L
H
7.4
43.9
|
| ImmunityBio Inc |
|
5,722.6
|
5.8
|
L
 -1.7%
H
5.7
6.0
|
L
 -20.8%
H
5.5
7.9
|
L
 184.8%
H
2.0
8.3
|
L
 140.1%
H
2.0
8.3
|
L
 83.9%
H
1.8
8.3
|
L
 45.3%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
| Ideaya Biosciences Inc |
|
2,817.6
|
32.1
|
L
 -2.6%
H
32.0
33.0
|
L
 -11.2%
H
32.0
36.2
|
L
 -7.8%
H
32.0
39.3
|
L
 -0.1%
H
28.8
39.3
|
L
 34.3%
H
13.5
39.3
|
L
 90.4%
H
13.3
47.7
|
L
 82.8%
H
8.1
47.7
|
L
H
3.0
47.7
|
| Inhibikase Therapeutics Inc |
|
189.2
|
1.6
|
L
 -0.6%
H
1.6
1.6
|
L
 -13.3%
H
1.6
1.9
|
L
 -20.4%
H
1.6
2.2
|
L
 9.1%
H
1.3
2.2
|
L
 -44.3%
H
1.3
3.3
|
L
 -60.5%
H
0.8
5.6
|
L
 -96.1%
H
0.8
55.0
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
313.5
|
5.9
|
L
 -0.5%
H
5.9
6.2
|
L
 12.8%
H
5.1
6.3
|
L
 7.4%
H
4.2
6.3
|
L
 59.1%
H
2.9
7.7
|
L
 187.4%
H
1.3
7.7
|
L
 146.7%
H
1.3
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
| Immuneering Corp (Class A) |
|
302.2
|
4.7
|
L
 -3.9%
H
4.7
5.1
|
L
 -12.4%
H
4.7
5.6
|
L
 -29.7%
H
4.0
8.5
|
L
 -25.1%
H
4.0
8.5
|
L
 145.0%
H
1.1
10.1
|
L
 5.2%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immunic Inc |
|
75.8
|
0.6
|
L
 3.3%
H
0.6
0.6
|
L
 -8.7%
H
0.6
0.7
|
L
 21.2%
H
0.5
0.7
|
L
 -21.3%
H
0.5
0.8
|
L
 -36.4%
H
0.5
1.4
|
L
 -71.9%
H
0.5
3.2
|
L
 -96.2%
H
0.5
28.2
|
L
 -99.8%
H
0.5
390
|
| Incyte |
|
19,608.7
|
99.9
|
L
 -1.2%
H
99.7
101.3
|
L
 -4.9%
H
98.9
105.1
|
L
 0.6%
H
97.9
112.3
|
L
 10.8%
H
91.2
112.3
|
L
 35.5%
H
53.6
112.3
|
L
 16.5%
H
50.3
112.3
|
L
 11.3%
H
50.3
112.3
|
L
 41.6%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
4.9
|
2.2
|
L
 -0.5%
H
2.2
2.2
|
L
 -23.0%
H
2.2
2.9
|
L
 -19.9%
H
2.2
3.7
|
L
 -34.7%
H
1.7
3.7
|
L
 137.0%
H
0.3
13.4
|
L
 30.5%
H
0.3
13.4
|
L
 -86.6%
H
0.3
36.8
|
L
 -99.4%
H
0.3
8800
|
| Indivior PLC |
|
4,303.3
|
34.4
|
L
 -0.8%
H
34.3
35.3
|
L
 2.6%
H
32.8
35.5
|
L
 -5.3%
H
31.7
37.7
|
L
 36.4%
H
28
38
|
L
 183.3%
H
7.6
38
|
L
 40.0%
H
7.3
38
|
L
 1866.9%
H
1.6
38
|
L
 1554.8%
H
0.4
38
|
| InMed Pharma Inc |
|
3.0
|
1.1
|
L
 0.9%
H
1.1
1.1
|
L
 0.9%
H
1.1
1.1
|
L
 -9.2%
H
1.0
1.4
|
L
 -42.6%
H
1.0
1.9
|
L
 -69.3%
H
1.0
8.0
|
L
 -97%
H
1.0
46.6
|
L
 -99.9%
H
1.0
3210
|
L
 -99.9%
H
1.0
32175
|
| Inovio Pharma Inc |
|
109.2
|
1.6
|
L
 -1.2%
H
1.6
1.6
|
L
 1.9%
H
1.5
1.6
|
L
 -8.1%
H
1.5
1.9
|
L
 -34.6%
H
1.5
2.7
|
L
 -21.7%
H
1.3
3.0
|
L
 -5.4%
H
0.3
14.8
|
L
 -87.5%
H
0.3
19
|
L
 -76.2%
H
0.3
33.8
|
| Insmed Inc |
|
33,556.4
|
157.3
|
L
 -0.3%
H
156.2
159.5
|
L
 -1.9%
H
153.1
165.5
|
L
 -10.8%
H
153.1
186.2
|
L
 -5.8%
H
153.1
212.8
|
L
 101.7%
H
60.4
212.8
|
L
 625.4%
H
16.0
212.8
|
L
 318.6%
H
16.0
212.8
|
L
 1092.0%
H
9.0
212.8
|
| Innoviva Inc |
|
1,477.4
|
19.8
|
L
 0.1%
H
19.7
19.9
|
L
 0.1%
H
19.4
20.0
|
L
 0.2%
H
19
20.2
|
L
 12.5%
H
17.5
22.8
|
L
 4.6%
H
16.5
22.8
|
L
 55.7%
H
10.6
22.8
|
L
 64.5%
H
10.6
22.8
|
L
 97.2%
H
7.6
22.8
|
| Ionis Pharma Inc |
|
13,439.0
|
83.0
|
L
 -1.1%
H
82.9
83.7
|
L
 1.4%
H
79.1
84.3
|
L
 3.7%
H
74.2
86.2
|
L
 15.4%
H
66.7
86.2
|
L
 152.3%
H
24.0
86.2
|
L
 107.3%
H
24.0
86.2
|
L
 38.1%
H
24.0
86.2
|
L
 113.1%
H
19.6
86.6
|
| Ironwood Pharma Inc (Class A) |
|
777.6
|
4.8
|
L
 -1.7%
H
4.7
4.9
|
L
 -11.3%
H
4.7
5.4
|
L
 48.9%
H
3.2
5.8
|
L
 216.6%
H
1.5
5.8
|
L
 28.5%
H
0.5
5.8
|
L
 -58.4%
H
0.5
15.7
|
L
 -53.2%
H
0.5
15.7
|
L
 -38.2%
H
0.5
17.7
|
| Iterum Therapeutics PLC |
|
16.5
|
0.3
|
L
H
0.3
0.3
|
L
 -11.4%
H
0.3
0.4
|
L
 6.9%
H
0.3
0.4
|
L
 -52.3%
H
0.3
0.7
|
L
 -79.3%
H
0.3
1.8
|
L
 -74.4%
H
0.3
3.0
|
L
 -98.5%
H
0.3
44.9
|
L
H
0.3
195
|
| I-Mab (ADR) |
|
424.2
|
3.7
|
L
 -4.9%
H
3.7
3.9
|
L
 -5.4%
H
3.7
4.1
|
L
 -8.7%
H
3.4
5.2
|
L
 -20.5%
H
3.4
5.2
|
L
 250.5%
H
0.6
6.8
|
L
 -45.9%
H
0.6
6.8
|
L
 -93.2%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immuron Ltd (ADR) |
|
7.4
|
0.9
|
L
H
0.9
0.9
|
L
 -9%
H
0.9
1.0
|
L
 8.3%
H
0.7
1.3
|
L
 -56.7%
H
0.7
2.1
|
L
 -54.7%
H
0.7
2.4
|
L
 -59.7%
H
0.7
6.0
|
L
 -86.9%
H
0.7
9.2
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
172.4
|
1.8
|
L
 4.0%
H
1.8
1.8
|
L
 3.4%
H
1.7
1.9
|
L
 8.2%
H
1.7
1.9
|
L
 -11.1%
H
1.6
2.4
|
L
 4.6%
H
1.6
2.6
|
L
 -46.7%
H
1.3
3.6
|
L
 -55.0%
H
1.3
12.0
|
L
H
1.3
12.0
|
| Jaguar Health Inc |
|
2.9
|
0.7
|
L
H
0.7
0.7
|
L
 -5.5%
H
0.7
0.8
|
L
 -33.0%
H
0.6
1.9
|
L
 -66.5%
H
0.6
2.1
|
L
 -22.5%
H
0.4
15.5
|
L
 -99.8%
H
0.4
302.4
|
L
 -100.0%
H
0.4
45090
|
L
 -100.0%
H
0.4
999999
|
| Jazz Pharma PLC |
|
9,962.4
|
164.0
|
L
 0.0%
H
162.7
165.1
|
L
 -4.1%
H
162.7
171.5
|
L
 -3.8%
H
157.0
175.8
|
L
 20.8%
H
128.8
183.0
|
L
 31.9%
H
95.5
183.0
|
L
 5.4%
H
95.5
183.0
|
L
 5.4%
H
95.5
189
|
L
 27.3%
H
86.9
189
|
| Kala Pharma Inc |
|
15.0
|
0.5
|
L
H
0.5
0.5
|
L
 -8.5%
H
0.5
0.6
|
L
 -6.9%
H
0.5
0.7
|
L
 -32.5%
H
0.5
1.9
|
L
 -93.9%
H
0.5
20.6
|
L
 -97.3%
H
0.5
24
|
L
 -99.9%
H
0.5
498.5
|
L
H
0.5
1337.5
|
| KalVista Pharma Inc |
|
779.9
|
15.4
|
L
 -1.4%
H
15.3
16
|
L
 -6.7%
H
14.6
16.6
|
L
 1.7%
H
14.2
19
|
L
 40.8%
H
10.4
19
|
L
 75.9%
H
8.7
19
|
L
 89.8%
H
6.3
19
|
L
 1.5%
H
4.1
45
|
L
 -54.6%
H
4.1
45
|
| Kiniksa Pharma Ltd (Class A) |
|
3,304.7
|
43.6
|
L
 -0.8%
H
43.6
44.6
|
L
 2.7%
H
41.5
45
|
L
 6.3%
H
37.0
45
|
L
 16.6%
H
36.6
45
|
L
 111.0%
H
18.1
45
|
L
 211.7%
H
10.3
45
|
L
 121.4%
H
7.4
45
|
L
H
5.0
45
|
| Kiora Pharma Inc |
|
8.4
|
2.3
|
L
 -0.4%
H
2.3
2.4
|
L
 3.6%
H
2.0
2.4
|
L
 19.9%
H
1.9
2.4
|
L
 -9.5%
H
1.8
2.6
|
L
 -42.0%
H
1.8
4.2
|
L
 -35.9%
H
0.4
8.5
|
L
 -99.1%
H
0.4
314
|
L
 -99.8%
H
0.4
3060
|
| Karyopharm Therapeutics Inc |
|
121.2
|
6.6
|
L
 -0.2%
H
6.5
6.8
|
L
 -0.3%
H
6.4
7.2
|
L
 -9.8%
H
5.9
9.0
|
L
 8.9%
H
5.0
9.0
|
L
 -33.2%
H
0.6
10.5
|
L
 -86.1%
H
0.6
73.1
|
L
 -97.1%
H
0.6
260.9
|
L
 -92.9%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
546.3
|
17.9
|
L
 -0.3%
H
17.8
18.3
|
L
 -7.9%
H
17.8
19.9
|
L
 -13.1%
H
17.5
20.7
|
L
 19.2%
H
14.9
22.6
|
L
 57.7%
H
9.1
22.6
|
L
 -69.1%
H
9.1
73
|
L
 -68.6%
H
9.1
76.0
|
L
H
9.1
88.8
|
| Pasithea Therapeutics Corp |
|
20.1
|
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 -4.4%
H
0.8
0.9
|
L
 -23.7%
H
0.8
1.3
|
L
 20.8%
H
0.3
2.1
|
L
 -64.9%
H
0.3
3.9
|
L
 24.3%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kazia Therapeutics Ltd (ADR) |
|
62.9
|
5.6
|
L
 -9.0%
H
5.5
6.4
|
L
 -20.7%
H
5.5
8.2
|
L
 -10.2%
H
5
8.2
|
L
 -27.8%
H
5
17.4
|
L
 -19.6%
H
2.9
17.4
|
L
 -88.9%
H
2.9
84
|
L
 -98.9%
H
2.9
744.5
|
L
 -98.7%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
18.7
|
0.8
|
L
 -1.3%
H
0.7
0.8
|
L
 -8.5%
H
0.7
0.9
|
L
 33.9%
H
0.5
0.9
|
L
 -21.9%
H
0.5
1.4
|
L
 -58.6%
H
0.5
1.9
|
L
 -74.5%
H
0.5
6.9
|
L
 -83.8%
H
0.5
12.5
|
L
 -78.7%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
318.8
|
8.5
|
L
H
8.4
8.7
|
L
 -0.9%
H
8.4
9.0
|
L
 3.2%
H
7.3
9.0
|
L
 20.5%
H
6.6
9.0
|
L
 40.7%
H
4.8
9.0
|
L
 27.8%
H
1.5
11.5
|
L
 -20.2%
H
1.5
12.9
|
L
 -29.3%
H
1.5
15.6
|
| Ligand Pharma Inc (Class B) |
|
3,783.8
|
192.3
|
L
 -1.5%
H
191.5
196.4
|
L
 -5.7%
H
189.3
205.9
|
L
 -1.5%
H
175.9
210.3
|
L
 4.2%
H
175.9
212.5
|
L
 61.7%
H
93.6
212.5
|
L
 173.5%
H
49.3
212.5
|
L
 60.7%
H
46.8
212.5
|
L
 198.0%
H
36.9
212.5
|
| Atyr Pharma Inc |
|
82.3
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 12%
H
0.7
0.9
|
L
 12%
H
0.7
0.9
|
L
 -13.4%
H
0.6
1.0
|
L
 -76.9%
H
0.6
7.3
|
L
 -64.6%
H
0.6
7.3
|
L
 -77.1%
H
0.6
13.1
|
L
 -98.9%
H
0.6
90.9
|
| Lipocine Inc |
|
49.7
|
9.0
|
L
 -0.3%
H
8.7
9.0
|
L
 -14.2%
H
8.7
11.1
|
L
 42.5%
H
5.9
12.4
|
L
 233.1%
H
2.5
12.4
|
L
 98.2%
H
2.5
12.4
|
L
 -1.4%
H
2.3
12.4
|
L
 -70.2%
H
2.3
38.8
|
L
 -94.2%
H
2.3
215.2
|
| Liquidia Corp |
|
3,677.3
|
42.3
|
L
 -1.8%
H
42.1
43.5
|
L
 2.9%
H
38.7
44.3
|
L
 21.6%
H
29.3
44.3
|
L
 88.3%
H
22.2
44.3
|
L
 196.4%
H
11.3
44.3
|
L
 532.8%
H
5.7
44.3
|
L
 1442.7%
H
2.3
44.3
|
L
H
2.3
44.3
|
| Lisata Therapeutics Inc |
|
41.2
|
4.7
|
L
 0.7%
H
4.6
4.7
|
L
 15.0%
H
4.0
4.9
|
L
 139.5%
H
1.8
4.9
|
L
 75.6%
H
1.8
4.9
|
L
 86.8%
H
1.8
4.9
|
L
 31.5%
H
1.8
4.9
|
L
 -85.3%
H
1.8
45.8
|
L
 -94.3%
H
1.8
199.5
|
| Lantern Pharma Inc |
|
35.7
|
3.2
|
L
 2.6%
H
3.1
3.3
|
L
 -9.6%
H
3.0
3.6
|
L
 -6.5%
H
2.9
3.6
|
L
 -16.5%
H
2.9
4.1
|
L
 -29.9%
H
2.6
5.7
|
L
 -40.0%
H
2.4
12.0
|
L
 -78.8%
H
2.4
23.5
|
L
H
2.4
24.8
|
| Lexicon Pharma Inc |
|
414.3
|
1.1
|
L
 -20.8%
H
1.1
1.3
|
L
 -35.2%
H
1.1
1.8
|
L
 -2.6%
H
1.1
1.8
|
L
 -14.3%
H
1.1
1.8
|
L
 39.0%
H
0.3
1.8
|
L
 -48.6%
H
0.3
3.8
|
L
 -85.6%
H
0.3
9.7
|
L
 -88.8%
H
0.3
19.6
|
| Lyra Therapeutics Inc |
|
3.4
|
1.9
|
L
 -4.9%
H
1.9
2.0
|
L
 -11.8%
H
1.6
2.3
|
L
 -43.1%
H
1.6
3.9
|
L
 -66.7%
H
1.6
6.5
|
L
 -78.7%
H
1.6
37.5
|
L
 -98.5%
H
1.6
339.5
|
L
 -99.6%
H
1.6
825
|
L
H
1.6
1100
|
| Legend Biotech Corp (ADR) |
|
3,171.1
|
17.2
|
L
 -3.1%
H
17.0
17.8
|
L
 -11.2%
H
17.0
19.9
|
L
 -21.7%
H
17.0
24.1
|
L
 -46.6%
H
17.0
33.5
|
L
 -52.4%
H
17.0
45.3
|
L
 -67.4%
H
17.0
77.3
|
L
 -32.1%
H
17.0
77.3
|
L
H
17.0
77.3
|
| Mustang Bio Inc |
|
7.1
|
1.0
|
L
H
1.0
1.0
|
L
 -9.4%
H
1.0
1.1
|
L
 1.0%
H
0.9
1.2
|
L
 -34.0%
H
0.9
1.5
|
L
 -80.2%
H
0.9
7
|
L
 -99.8%
H
0.1
547.5
|
L
 -100.0%
H
0.1
3667.5
|
L
H
0.1
10012.5
|
| Moleculin Biotech Inc |
|
13.1
|
4.3
|
L
 -0.7%
H
4.3
4.4
|
L
 -10.9%
H
4.2
4.9
|
L
 23.6%
H
3.1
5.2
|
L
 -64.6%
H
3.1
15.8
|
L
 -89.0%
H
3.1
91.3
|
L
 -99.1%
H
3.1
3318.8
|
L
 -99.8%
H
3.1
3318.8
|
L
H
3.1
21555
|
| Madrigal Pharma Inc |
|
11,125.2
|
489.9
|
L
 -1.0%
H
480.0
491.4
|
L
 -1.6%
H
466.0
506.4
|
L
 -16.9%
H
466.0
598.8
|
L
 16.2%
H
399
615
|
L
 50.1%
H
265
615
|
L
 69.2%
H
119.8
615
|
L
 312.5%
H
52.3
615
|
L
 5615.9%
H
5.3
615
|
| MediWound Ltd |
|
232.2
|
18.1
|
L
 2.7%
H
17.0
18.1
|
L
 3.4%
H
17.0
18.7
|
L
 -3.1%
H
16.3
19.7
|
L
 0.1%
H
16.3
19.7
|
L
 -9.4%
H
14.1
22.5
|
L
 27.7%
H
7.1
24
|
L
 -46.5%
H
7.1
43.5
|
L
 -61.8%
H
7.1
62.3
|
| MEI Pharma Inc |
|
44.5
|
1.2
|
L
 -3.2%
H
1.2
1.3
|
L
 -8.3%
H
1.2
1.3
|
L
 -9.0%
H
1.2
1.7
|
L
 -41.8%
H
1.2
2.3
|
L
 -58.0%
H
1.2
9
|
L
 -80.4%
H
1.2
9
|
L
 -98.1%
H
1.2
91.5
|
L
 -95.2%
H
1.2
102.8
|
| Macrogenics Inc |
|
113.9
|
1.8
|
L
 -6.7%
H
1.8
1.9
|
L
 2.3%
H
1.7
2.0
|
L
 12.5%
H
1.5
2.0
|
L
 6.5%
H
1.3
2.0
|
L
 -40.6%
H
1.0
3.2
|
L
 -68.6%
H
1.0
21.9
|
L
 -91.2%
H
1.0
36.5
|
L
 -91.1%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
6.4
|
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 -27.8%
H
0.4
0.6
|
L
 -40.9%
H
0.4
1.0
|
L
 -82.1%
H
0.4
2.4
|
L
 -85.3%
H
0.4
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
53.4
|
L
 5.7%
H
50.8
54.6
|
L
 1.1%
H
48.9
54.6
|
L
 28.2%
H
35.8
54.6
|
L
 57.8%
H
32.3
54.6
|
L
 171%
H
16.6
54.6
|
L
 625%
H
7.2
54.6
|
L
 -62.3%
H
5.1
227.2
|
L
H
5.1
336
|
| Mirum Pharma Inc |
|
6,106.0
|
102.0
|
L
 -0.9%
H
101.5
103.7
|
L
 6.2%
H
93.2
103.8
|
L
 27.1%
H
73.8
103.8
|
L
 44.7%
H
63.2
103.8
|
L
 109.8%
H
36.9
103.8
|
L
 327.2%
H
20.8
103.8
|
L
 462.7%
H
12.8
103.8
|
L
H
6.5
103.8
|
| Milestone Pharma Inc |
|
160.1
|
1.9
|
L
 -0.5%
H
1.9
1.9
|
L
 -5.5%
H
1.9
2.0
|
L
 -7.8%
H
1.9
2.3
|
L
 2.2%
H
1.6
3.1
|
L
 -6%
H
0.6
3.1
|
L
 -46.3%
H
0.6
4.5
|
L
 -74.5%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,122.9
|
15.9
|
L
 -2.2%
H
15.8
16.4
|
L
 1.5%
H
15.2
16.6
|
L
 15.7%
H
11.1
18.8
|
L
 64.9%
H
9.5
18.8
|
L
 -65.6%
H
6.0
62.8
|
L
 32.6%
H
6.0
65.0
|
L
 44.1%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mannkind Corp |
|
1,790.2
|
5.8
|
L
 0.7%
H
5.8
5.9
|
L
 -1.4%
H
5.4
6.0
|
L
 1.0%
H
5.0
6.5
|
L
 5.2%
H
4.9
6.5
|
L
 -4.6%
H
3.4
6.5
|
L
 11.5%
H
3.2
7.6
|
L
 65.6%
H
2.5
7.6
|
L
 16.8%
H
0.7
11.2
|
| Mind Medicine Inc |
|
1,663.4
|
17.1
|
L
 -0.8%
H
17.0
17.8
|
L
 0.8%
H
16.4
17.8
|
L
 27.1%
H
12.9
18.1
|
L
 32.5%
H
10.5
18.1
|
L
 133.7%
H
4.7
18.1
|
L
 397.4%
H
2.4
18.1
|
L
 -61.3%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
88.5
|
1.8
|
L
 2.9%
H
1.8
1.8
|
L
 8.4%
H
1.7
1.9
|
L
 40.6%
H
1.3
1.9
|
L
 52.5%
H
1.2
2.0
|
L
 -10.9%
H
1.1
2.1
|
L
 -26.8%
H
1.1
2.7
|
L
 -68.8%
H
1.1
10.8
|
L
 -55.3%
H
1.1
14.5
|
| TNF Pharma Inc |
|
18.2
|
4.4
|
L
 -2.7%
H
4.4
4.8
|
L
 7.4%
H
3.9
6.3
|
L
 3.3%
H
3.9
6.3
|
L
 15%
H
2.5
8.2
|
L
 -95.9%
H
2.5
106
|
L
 -99.9%
H
2.5
8940
|
L
 -99.9%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| NewAmsterdam Pharma Co NV |
|
3,500.4
|
30.9
|
L
 -1.8%
H
30.5
31.7
|
L
 -11.3%
H
30.5
35.0
|
L
 -11.9%
H
30.2
37.1
|
L
 -13.9%
H
30.2
42
|
L
 48.6%
H
14.1
42
|
L
 89.6%
H
5.6
42
|
L
H
5.6
42
|
L
H
5.6
42
|
| Neurocrine Biosciences Inc |
|
13,576.9
|
136.2
|
L
 -1.3%
H
135.0
138.0
|
L
 -0.9%
H
132.8
138.7
|
L
 -5.2%
H
129.2
143.2
|
L
 -1.3%
H
129.2
160.2
|
L
 -9.6%
H
84.2
160.2
|
L
 25.8%
H
84.2
160.2
|
L
 24.1%
H
71.9
160.2
|
L
 220.0%
H
31.3
160.2
|
| Minerva Neurosciences Inc |
|
181.3
|
4.2
|
L
 -0.2%
H
4.2
4.3
|
L
 7.4%
H
3.9
4.5
|
L
 2.4%
H
3.8
4.9
|
L
 -1.0%
H
3.3
4.9
|
L
 66.9%
H
1.2
12.5
|
L
 77.5%
H
1.2
13.5
|
L
 -83.6%
H
1.2
29.5
|
L
 -89.9%
H
1.2
126.7
|
| Nektar Therapeutics |
|
704.8
|
34.7
|
L
 -1.7%
H
34.1
35.2
|
L
 -5.2%
H
34.1
39.8
|
L
 -18.9%
H
34.1
45.3
|
L
 -41.9%
H
34.1
66.9
|
L
 175.9%
H
6.5
66.9
|
L
 -11.5%
H
6.2
66.9
|
L
 -88.3%
H
6.2
401.3
|
L
 -83.1%
H
6.2
1670.4
|
| NLS Pharmaceutics Ltd |
|
11.6
|
2.6
|
L
H
2.5
2.7
|
L
 -4.1%
H
2.5
3.1
|
L
 19.2%
H
1.9
3.1
|
L
 -65.5%
H
1.9
8.3
|
L
 -87.0%
H
1.9
33.7
|
L
 -99.5%
H
1.2
704
|
L
 -99.8%
H
1.2
2940
|
L
H
1.2
2940
|
| Nurix Therapeutics Inc |
|
1,743.2
|
17.0
|
L
 -3.6%
H
16.7
17.5
|
L
 -12.6%
H
16.7
19.7
|
L
 -12.5%
H
16.7
20.2
|
L
 44.9%
H
11.5
22.5
|
L
 -13.7%
H
8.2
22.5
|
L
 36.9%
H
4.2
29.6
|
L
 -53.4%
H
4.2
47.8
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
27.0
|
0.9
|
L
 -4.2%
H
0.9
1.0
|
L
 -3.2%
H
0.9
1.0
|
L
 19.7%
H
0.7
1.1
|
L
 -14.2%
H
0.7
1.3
|
L
 -12.5%
H
0.7
2.6
|
L
 -46.2%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
62.8
|
2.1
|
L
H
2.1
2.2
|
L
 -9.4%
H
2.0
2.3
|
L
 -18.5%
H
2
2.8
|
L
 -30.5%
H
2.0
3.4
|
L
 -32.5%
H
1.6
3.8
|
L
 -82.8%
H
1.1
54
|
L
 -99.6%
H
1.1
642
|
L
H
1.1
769.9
|
| Nuvectis Pharma Inc |
|
212.6
|
8.3
|
L
 -2.6%
H
8.3
8.6
|
L
 -5.3%
H
8.2
8.8
|
L
 8.1%
H
7.2
9.4
|
L
 22.6%
H
5.6
9.4
|
L
 30.3%
H
5.6
11.5
|
L
 4.0%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
39.0
|
11.1
|
L
 6.8%
H
10.4
11.1
|
L
 -12.0%
H
10.4
12.6
|
L
 -15.8%
H
10.4
14.6
|
L
 -7.0%
H
8.1
15.7
|
L
 16.1%
H
2.8
15.7
|
L
 -44.5%
H
2.8
30.8
|
L
 -92.0%
H
2.8
172.8
|
L
H
2.8
1308
|
| Ocugen Inc |
|
484.4
|
1.5
|
L
 -2.6%
H
1.5
1.5
|
L
 -10.3%
H
1.5
1.7
|
L
H
1.3
2.0
|
L
 -1.3%
H
1.1
2.0
|
L
 100%
H
0.5
2.0
|
L
 16.5%
H
0.3
2.1
|
L
 -16.4%
H
0.3
18.8
|
L
 -99.2%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,629.0
|
28.2
|
L
 -0.2%
H
28.2
29.0
|
L
 5.5%
H
26.1
29.0
|
L
 40.9%
H
19.6
29.0
|
L
 30.8%
H
18.6
29.0
|
L
 27.2%
H
14
29.0
|
L
 177.9%
H
6.3
29.0
|
L
H
6.3
29.0
|
L
H
6.3
29.0
|
| Ocular Therapeutix Inc |
|
2,024.0
|
9.5
|
L
 -4.5%
H
9.4
10.0
|
L
 -14.6%
H
9.4
11.2
|
L
 -22.8%
H
9.4
13.0
|
L
 -17.3%
H
9.4
16.4
|
L
 21.2%
H
5.8
16.4
|
L
 144.8%
H
2
16.4
|
L
 -47.7%
H
2
21.5
|
L
 55.2%
H
2
24.3
|
| Opus Genetics Inc |
|
160.7
|
2.3
|
L
 -6.8%
H
2.3
2.5
|
L
 -6.8%
H
2.3
3.1
|
L
 17.1%
H
1.9
3.1
|
L
 17.7%
H
1.7
3.1
|
L
 115.7%
H
0.7
3.1
|
L
 -31.7%
H
0.7
6.6
|
L
 -80.0%
H
0.7
13.8
|
L
 -98.7%
H
0.7
340.8
|
| Olema Pharma Inc |
|
2,035.3
|
25.4
|
L
 -2.6%
H
25.1
26.2
|
L
 -3.9%
H
24.3
26.6
|
L
 -1.0%
H
23.9
29.5
|
L
 193.9%
H
7.8
36.3
|
L
 308.9%
H
2.9
36.3
|
L
 439.1%
H
2.9
36.3
|
L
 -40.2%
H
2
54.9
|
L
H
2
60.3
|
| Omeros Corp |
|
833.8
|
11.8
|
L
 -1.6%
H
11.7
12.2
|
L
 -3.2%
H
11.5
12.7
|
L
 -29.0%
H
11.5
17.6
|
L
 53.1%
H
6.2
17.7
|
L
 35.6%
H
3.0
17.7
|
L
 335.6%
H
0.9
17.7
|
L
 -39.6%
H
0.9
23.9
|
L
 9.0%
H
0.9
27.1
|
| ORIC Pharma Inc |
|
1,015.8
|
10.4
|
L
 -3.1%
H
10.3
10.9
|
L
 -13.4%
H
10.3
12.6
|
L
 26.4%
H
7.8
12.7
|
L
 -19.3%
H
7.8
13.6
|
L
 -6.5%
H
3.9
14.9
|
L
 70.1%
H
3.9
16.7
|
L
 -64.4%
H
2.4
37
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
133.3
|
3.4
|
L
 -2.1%
H
3.3
3.4
|
L
 0.9%
H
3.3
3.6
|
L
 15.1%
H
2.8
3.7
|
L
 41.4%
H
2.1
3.7
|
L
 48.9%
H
1.8
3.7
|
L
 72.7%
H
1.7
5.3
|
L
 -53.9%
H
1.7
31.5
|
L
 -47.7%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
33.1
|
0.5
|
L
 -2.2%
H
0.4
0.5
|
L
 -11.8%
H
0.4
0.5
|
L
 -77.3%
H
0.4
2.0
|
L
 -64.8%
H
0.4
2.5
|
L
 -77.4%
H
0.4
3.0
|
L
 -99.9%
H
0.4
812
|
L
 -99.9%
H
0.4
1704
|
L
H
0.4
17568
|
| Ovid Therapeutics Inc |
|
108.2
|
1.5
|
L
 -1.9%
H
1.5
1.6
|
L
 -13.1%
H
1.5
1.8
|
L
 -7.9%
H
1.5
1.9
|
L
 4.8%
H
1.2
1.9
|
L
 105.4%
H
0.2
2.0
|
L
 -39.9%
H
0.2
4.1
|
L
 -45.9%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,608.8
|
39.7
|
L
 -0.5%
H
39.5
40.0
|
L
 -4.6%
H
38.3
41.3
|
L
 5.2%
H
36.5
42.8
|
L
 -3.6%
H
36.1
46.4
|
L
 81.2%
H
16.2
46.4
|
L
 160.3%
H
9.4
46.4
|
L
 91.4%
H
9.4
46.4
|
L
 18.3%
H
9.4
54.6
|
| Palisade Bio Inc |
|
234.2
|
1.6
|
L
 -2.5%
H
1.6
1.6
|
L
 -15.1%
H
1.6
2.0
|
L
 -36.7%
H
1.6
2.6
|
L
 -25.9%
H
1.5
2.6
|
L
 9.8%
H
0.5
2.6
|
L
 -95.3%
H
0.4
54.8
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
1275300
|
| Puma biotech Inc |
|
322.0
|
6.4
|
L
 -0.6%
H
6.4
6.5
|
L
 -6.9%
H
6.3
6.9
|
L
 4.9%
H
5.6
7.2
|
L
 23.8%
H
4.6
7.2
|
L
 108.1%
H
2.6
7.2
|
L
 50.7%
H
2.1
7.7
|
L
 -45.6%
H
1.6
14.1
|
L
 -84.7%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
829.0
|
20.2
|
L
 0.4%
H
20
20.4
|
L
 -2.9%
H
19.7
21.1
|
L
 -22.6%
H
18.8
26.8
|
L
 -4%
H
18.8
27.2
|
L
 -22.5%
H
18.8
27.6
|
L
 -48.8%
H
11.2
48.6
|
L
 -69.5%
H
11.2
82.2
|
L
 -66.1%
H
11.2
82.2
|
| Processa Pharma Inc |
|
6.9
|
3.1
|
L
 -2.9%
H
3.1
3.1
|
L
 -3.8%
H
3
3.5
|
L
 -10.6%
H
2.8
3.8
|
L
 -68.6%
H
2.8
10.3
|
L
 -79.4%
H
2.8
20.2
|
L
 -99.3%
H
2.8
635
|
L
 -99.9%
H
2.8
7120
|
L
 -100.0%
H
2.8
17937.5
|
| PDS biotech Corp |
|
46.5
|
0.9
|
L
 -2.3%
H
0.9
0.9
|
L
 -12.4%
H
0.8
1.1
|
L
 4.9%
H
0.8
1.2
|
L
 -15.8%
H
0.7
1.2
|
L
 -44.1%
H
0.7
2.2
|
L
 -91.1%
H
0.7
10.3
|
L
 -72.1%
H
0.7
17.9
|
L
 -99.6%
H
0.6
355.4
|
| Phathom Pharma Inc |
|
1,043.8
|
13.4
|
L
 -1.1%
H
13.3
13.6
|
L
 -5.7%
H
13.1
14.3
|
L
 -22.3%
H
13.1
18.1
|
L
 -1.1%
H
12.3
18.3
|
L
 104.3%
H
2.2
18.3
|
L
 8.3%
H
2.2
19.7
|
L
 -65.2%
H
2.2
50.8
|
L
H
2.2
64.5
|
| Pharvaris NV |
|
1,776.0
|
27.3
|
L
 -1.6%
H
27.3
27.9
|
L
 -2.3%
H
26.7
28.3
|
L
 6.2%
H
23.6
28.5
|
L
 23.8%
H
21.0
29.8
|
L
 55.0%
H
11.5
29.8
|
L
 189.0%
H
6.0
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
| Praxis Precision Medicines Inc |
|
8,766.0
|
316.0
|
L
 0.6%
H
311.9
316.1
|
L
 3.8%
H
289.5
323.4
|
L
 3.8%
H
266.9
326.9
|
L
 61.4%
H
154.5
326.9
|
L
 326.9%
H
26.7
326.9
|
L
 342.6%
H
11.9
326.9
|
L
 -58.6%
H
11.9
828.9
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
2.8
|
0.7
|
L
 1.4%
H
0.7
0.7
|
L
 -21.7%
H
0.7
0.9
|
L
H
0.6
1.6
|
L
 -42.9%
H
0.6
1.6
|
L
 -78.4%
H
0.6
5.5
|
L
 -97.6%
H
0.2
158.5
|
L
 -99.7%
H
0.2
470.4
|
L
H
0.2
471
|
| ProQR Therapeutics NV |
|
169.6
|
1.6
|
L
 0.6%
H
1.6
1.7
|
L
 -5.9%
H
1.6
1.8
|
L
 -21.1%
H
1.6
2.3
|
L
 -39.3%
H
1.6
2.8
|
L
 -19.1%
H
1.1
3.1
|
L
 -44.3%
H
1.1
4.6
|
L
 -65.3%
H
0.5
9.5
|
L
 -69.4%
H
0.5
24
|
| Plus Therapeutics Inc |
|
42.8
|
0.2
|
L
H
0.2
0.2
|
L
 -14.3%
H
0.2
0.3
|
L
 -56.4%
H
0.2
0.6
|
L
 -55.6%
H
0.2
0.8
|
L
 -80%
H
0.2
2.3
|
L
 -96.4%
H
0.2
7.1
|
L
 -99.3%
H
0.2
81.3
|
L
 -100.0%
H
0.2
40500
|
| PTC Therapeutics Inc |
|
6,074.6
|
75.7
|
L
 -1.0%
H
75.0
77.6
|
L
 -0.7%
H
73.8
78.4
|
L
 -2.6%
H
69.8
80.2
|
L
 12.3%
H
66.1
87.5
|
L
 67.3%
H
36.0
87.5
|
L
 63.6%
H
17.5
87.5
|
L
 30.9%
H
17.5
87.5
|
L
 217.6%
H
4.0
87.5
|
| Pulmatrix Inc |
|
9.3
|
2.6
|
L
 -2.3%
H
2.6
2.6
|
L
 -4.5%
H
2.5
2.9
|
L
 15.3%
H
2.2
3.0
|
L
 -47.5%
H
2.2
5.0
|
L
 -67.6%
H
2.2
10.4
|
L
 -37.1%
H
1.6
10.4
|
L
 -90.9%
H
1.6
60.8
|
L
 -99.6%
H
1.6
1396
|
| Polypid Ltd |
|
76.9
|
4.6
|
L
 -1.9%
H
4.6
4.8
|
L
 -4.0%
H
4.5
5.0
|
L
 5.2%
H
4.1
5.1
|
L
 21.6%
H
3.5
5.1
|
L
 55.0%
H
2.3
5.1
|
L
 -81.5%
H
2.3
26.4
|
L
 -98.4%
H
2.3
495
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
93.4
|
1.5
|
L
 -3.9%
H
1.5
1.6
|
L
 -12.3%
H
1.5
1.7
|
L
 41.5%
H
1.1
2.2
|
L
 -54.7%
H
1.0
5.6
|
L
 -2.6%
H
0.8
5.6
|
L
 -5.7%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
1,435.9
|
20.6
|
L
 -0.4%
H
20.6
20.8
|
L
 3.4%
H
19.7
21.3
|
L
 21.7%
H
16.6
21.3
|
L
 53.7%
H
12.7
21.3
|
L
 133.1%
H
7.5
21.3
|
L
 44.6%
H
6.7
21.3
|
L
 44.1%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
5.6
|
0.6
|
L
H
0.6
0.6
|
L
 -4.6%
H
0.6
0.7
|
L
 -8.8%
H
0.6
0.7
|
L
 -41.5%
H
0.6
1.0
|
L
 -81.6%
H
0.5
3.5
|
L
 -98.1%
H
0.5
47.4
|
L
 -99.2%
H
0.5
145
|
L
 -99.9%
H
0.5
1390
|
| Qilian Intl Holding Grp ltd (Class A) |
|
718.2
|
3.6
|
L
H
3.3
3.7
|
L
 -7.5%
H
3.3
4.0
|
L
 -13.1%
H
3.3
4.3
|
L
 -61.4%
H
3.3
10.1
|
L
 -60.9%
H
3.3
17.2
|
L
 -46.2%
H
1.8
17.2
|
L
 -89.7%
H
1.8
42.4
|
L
H
1
110
|
| Quoin Pharma Ltd (ADR) |
|
13.0
|
8.1
|
L
 -3.0%
H
8.1
8.4
|
L
 -16.7%
H
8.1
10.3
|
L
 -44.3%
H
8.1
14.7
|
L
 -34.6%
H
8.1
23.5
|
L
 -96.3%
H
5.1
329
|
L
 -99.9%
H
5.1
23688
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| RAPT Therapeutics Inc |
|
1,669.3
|
57.6
|
L
 0.0%
H
57.6
57.7
|
L
H
57.6
57.7
|
L
 60.8%
H
29.8
57.7
|
L
 93.6%
H
26.5
57.7
|
L
 515.8%
H
5.7
57.7
|
L
 -74.2%
H
5.7
251.6
|
L
 -63.8%
H
5.7
346.1
|
L
H
5.7
409.7
|
| Ultragenyx Pharmaceutical Inc |
|
2,283.6
|
23.7
|
L
 -2.5%
H
23.5
24.6
|
L
 1.2%
H
23.2
25
|
L
 20.0%
H
19.8
25.1
|
L
 -31.6%
H
18.4
39.9
|
L
 -44.3%
H
18.4
46.5
|
L
 -45.9%
H
18.4
60.4
|
L
 -82.9%
H
18.4
175
|
L
 -57.8%
H
18.4
179.7
|
| Regeneron Pharma |
|
78,486.2
|
746.8
|
L
 -0.4%
H
735.6
774.4
|
L
 -1.2%
H
735.6
776.3
|
L
 -4.3%
H
718.4
821.1
|
L
 14.4%
H
625.1
821.1
|
L
 8.7%
H
476.5
821.1
|
L
 0.5%
H
476.5
1211.2
|
L
 48.2%
H
441
1211.2
|
L
 77.8%
H
271.4
1211.2
|
| Regencell Bioscience Holdings Ltd |
|
12,822.1
|
25.9
|
L
 -7.1%
H
24.8
27.7
|
L
 -15.7%
H
24.8
37.8
|
L
 10.4%
H
20.5
69
|
L
 56.1%
H
10.3
69
|
L
 25830%
H
0.1
83.6
|
L
 3182.3%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
8,664.8
|
153.9
|
L
 -1.6%
H
153.2
157.4
|
L
 -8.3%
H
152.5
169.8
|
L
 -7.1%
H
152.5
175.8
|
L
 3.7%
H
139.4
175.8
|
L
 -9.1%
H
103.0
177.2
|
L
 -21.1%
H
103.0
211.1
|
L
 -23.0%
H
103.0
327.3
|
L
 594.9%
H
20.1
327.3
|
| Regenxbio Inc |
|
566.0
|
11.2
|
L
 -3.6%
H
11.0
11.4
|
L
 -30.0%
H
9.5
16
|
L
 -21.8%
H
9.5
16.2
|
L
 -12.9%
H
9.5
16.2
|
L
 48.7%
H
5.0
16.2
|
L
 -51.7%
H
5.0
28.8
|
L
 -72.9%
H
5.0
49.5
|
L
 -19.6%
H
5.0
85.1
|
| Rigel Pharma |
|
632.2
|
34.8
|
L
 -0.9%
H
34.6
35.4
|
L
 -8.2%
H
34.6
37.8
|
L
 -19.2%
H
34.6
49.1
|
L
 18.5%
H
28.1
52.2
|
L
 54.9%
H
15.5
52.2
|
L
 1835%
H
0.7
52.2
|
L
 856.9%
H
0.6
52.2
|
L
 1166.5%
H
0.6
52.2
|
| Relmada Therapeutics Inc |
|
274.3
|
3.7
|
L
 -4.4%
H
3.7
3.9
|
L
 -5.6%
H
3.7
4.5
|
L
 -16.0%
H
3.6
5.0
|
L
 52.7%
H
2.2
5.1
|
L
 938.9%
H
0.2
5.1
|
L
 -9.2%
H
0.2
7.2
|
L
 -88.6%
H
0.2
40
|
L
 -32.7%
H
0.2
54
|
| RenovoRx Inc |
|
35.6
|
1.0
|
L
 1.0%
H
1.0
1
|
L
 -4.9%
H
0.9
1.0
|
L
 18.3%
H
0.8
1.3
|
L
 -7.6%
H
0.7
1.3
|
L
 -28.7%
H
0.7
1.5
|
L
 -63.4%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
15,050.4
|
21.6
|
L
 -1.7%
H
21.5
22.0
|
L
 -5.8%
H
21.5
23.4
|
L
 -0.3%
H
20.8
23.9
|
L
 15.4%
H
18.7
23.9
|
L
 94.4%
H
8.7
23.9
|
L
 153.1%
H
6.6
23.9
|
L
 109.7%
H
2.5
23.9
|
L
H
2.5
23.9
|
| Royalty Pharma PLC (Class A) |
|
17,585.5
|
41.2
|
L
 0.7%
H
40.9
41.3
|
L
 2.6%
H
40.0
41.3
|
L
 5.3%
H
38.3
41.7
|
L
 12.2%
H
36.0
41.7
|
L
 28.8%
H
29.7
41.7
|
L
 5.8%
H
24.1
41.7
|
L
 -12.4%
H
24.1
50.2
|
L
H
24.1
56.5
|
| Reviva Pharma Holdings Inc |
|
33.9
|
0.3
|
L
 -3.3%
H
0.3
0.3
|
L
 -14.7%
H
0.3
0.3
|
L
H
0.3
0.4
|
L
 -50.9%
H
0.3
0.8
|
L
 -83.8%
H
0.3
2.2
|
L
 -93.3%
H
0.3
9.3
|
L
 -96.4%
H
0.3
9.5
|
L
H
0.3
15.1
|
| Rezolute Inc |
|
301.4
|
3.3
|
L
H
3.2
3.3
|
L
 -0.6%
H
3.1
3.7
|
L
 33.7%
H
1.9
3.7
|
L
 -65.9%
H
1.1
11.5
|
L
 -35.8%
H
1.1
11.5
|
L
 49.8%
H
0.7
11.5
|
L
 -79.6%
H
0.7
17.5
|
L
 -95%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
6.2
|
1.2
|
L
 -3.9%
H
1.2
1.3
|
L
 -8.3%
H
1.2
1.4
|
L
 11.9%
H
0.9
1.4
|
L
 -16.4%
H
0.9
1.6
|
L
 -79.9%
H
0.9
6.3
|
L
 -99.4%
H
0.9
276
|
L
 -100.0%
H
0.9
11520
|
L
 -100.0%
H
0.9
16540
|
| Sunshine Biopharma Inc |
|
6.1
|
1.3
|
L
 0.8%
H
1.2
1.3
|
L
H
1.2
1.4
|
L
 1.6%
H
1.2
1.4
|
L
 -29.0%
H
1.2
1.9
|
L
 -56.6%
H
1.2
3.9
|
L
 -98.8%
H
0.1
140
|
L
 -99.9%
H
0.1
6280
|
L
 -100.0%
H
0.1
224000
|
| Scilex Holding Co |
|
59.4
|
8.4
|
L
 -2.9%
H
8.3
9.0
|
L
 -26.8%
H
8.2
12.3
|
L
 -38.3%
H
8.2
14.2
|
L
 -54.2%
H
8.2
27
|
L
 1775.6%
H
0.2
34.3
|
L
 -4.2%
H
0.2
34.3
|
L
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
30.2
|
0.7
|
L
 -2.7%
H
0.7
0.7
|
L
 -5.3%
H
0.7
0.9
|
L
 16.1%
H
0.6
0.9
|
L
 4.4%
H
0.6
0.9
|
L
 -30.8%
H
0.6
1.3
|
L
 -58.6%
H
0.6
3.9
|
L
 -90.4%
H
0.6
10.3
|
L
 -98.4%
H
0.6
55.5
|
| Shuttle Pharma Holdings Inc |
|
4.1
|
2.1
|
L
 -2.3%
H
2.1
2.2
|
L
 -9.3%
H
1.9
2.7
|
L
 27.4%
H
1.3
4.4
|
L
 -31.6%
H
1.3
4.4
|
L
 -88.6%
H
1.3
20.7
|
L
 -99.5%
H
1.3
550
|
L
H
1.3
25252
|
L
H
1.3
25252
|
| SIGA Tech Inc |
|
477.6
|
6.7
|
L
 -2.1%
H
6.6
6.8
|
L
 -0.9%
H
6.6
6.9
|
L
 6.7%
H
6.1
6.9
|
L
 -18.0%
H
5.7
8.5
|
L
 6.6%
H
5.0
9.6
|
L
 -10.0%
H
4.2
12.8
|
L
 3.3%
H
4.2
27.0
|
L
 1350%
H
0.4
27.0
|
| SILO Pharma Inc |
|
4.5
|
0.3
|
L
 3.0%
H
0.3
0.4
|
L
 -8.1%
H
0.3
0.4
|
L
 3.0%
H
0.3
0.4
|
L
 -37.0%
H
0.3
0.6
|
L
 -81.5%
H
0.3
1.9
|
L
 -86.7%
H
0.3
4.5
|
L
 -98.1%
H
0.3
496
|
L
 -99.3%
H
0.3
496
|
| Sol-Gel Tech Ltd |
|
165.3
|
59.3
|
L
 -2.5%
H
58.5
59.6
|
L
 3.2%
H
48.3
65.2
|
L
 33.2%
H
40.6
75
|
L
 60.3%
H
28.8
75
|
L
 7223.5%
H
0.4
75
|
L
 1049.6%
H
0.3
75
|
L
 509.7%
H
0.3
75
|
L
H
0.3
75
|
| Soleno Therapeutics Inc |
|
2,140.3
|
39.9
|
L
 -1.7%
H
39.6
40.8
|
L
 -8.9%
H
39.6
44.5
|
L
 -16.2%
H
39.4
50.9
|
L
 -43.0%
H
39.4
72.8
|
L
 -19.3%
H
39.4
90.3
|
L
 1318.1%
H
1.8
90.3
|
L
 35.5%
H
0.9
90.3
|
L
 -60.3%
H
0.9
131.3
|
| SELLAS Life Sciences Grp Inc |
|
643.7
|
3.8
|
L
 -2.8%
H
3.7
3.9
|
L
 -16.2%
H
3.7
4.7
|
L
 12.8%
H
3.2
5.2
|
L
 81.7%
H
1.4
5.2
|
L
 209.8%
H
1.0
5.2
|
L
 16.3%
H
0.5
5.2
|
L
 -38.0%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Soligenix Inc |
|
13.0
|
1.3
|
L
 -1.5%
H
1.3
1.3
|
L
 -9.2%
H
1.3
1.4
|
L
 -8.5%
H
1.3
1.5
|
L
 -17.8%
H
1.2
1.7
|
L
 -46.7%
H
1.1
6.2
|
L
 -98.9%
H
1.1
120.8
|
L
 -99.7%
H
1.1
595.2
|
L
 -99.9%
H
1.1
2292.1
|
| Sonoma Pharma Inc |
|
5.6
|
3.3
|
L
 -0.6%
H
3.3
3.3
|
L
 -3.5%
H
3.3
3.5
|
L
 -6.7%
H
3.2
3.9
|
L
 -17%
H
3.1
4.0
|
L
 23.4%
H
1.8
6.9
|
L
 64.4%
H
0.1
6.9
|
L
 -59.4%
H
0.1
13.4
|
L
 -94.1%
H
0.1
74.2
|
| Synaptogenix Inc |
|
32.8
|
4.4
|
L
 -4.8%
H
4.2
4.6
|
L
 -6.8%
H
4.2
5.3
|
L
 11.1%
H
3.5
5.9
|
L
 -43.8%
H
3.5
9
|
L
 23.3%
H
1.8
12.0
|
L
 300%
H
0.1
12.0
|
L
 -16.0%
H
0.1
14.5
|
L
H
0.1
14.5
|
| SciSparc Ltd |
|
3.3
|
0.8
|
L
 -2.5%
H
0.8
0.8
|
L
 -23.8%
H
0.8
1.0
|
L
 -43.8%
H
0.8
1.6
|
L
 -77.4%
H
0.8
3.4
|
L
 -92.4%
H
0.8
12.1
|
L
 -99.8%
H
0.8
726.2
|
L
H
0.8
4641
|
L
H
0.8
4641
|
| ARS Pharma Inc |
|
984.5
|
10.0
|
L
 -2.5%
H
9.9
10.3
|
L
 -5.8%
H
9.9
10.9
|
L
 -15.0%
H
9.9
13.2
|
L
 10.9%
H
6.7
13.2
|
L
 -30.5%
H
6.7
18.9
|
L
 57.6%
H
2.6
18.9
|
L
 -77.3%
H
2.6
63.4
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
170.0
|
3.4
|
L
 -2.6%
H
3.1
3.6
|
L
 -9.6%
H
2.8
4
|
L
 162.8%
H
1.3
4
|
L
 27.4%
H
1.2
4
|
L
 30.4%
H
1.2
5.3
|
L
 637.0%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
2,163.9
|
20.7
|
L
 -2.8%
H
20.4
21.3
|
L
 -5.2%
H
20.4
24.7
|
L
 -5.4%
H
20.1
24.7
|
L
 -11.9%
H
15.1
24.7
|
L
 -82.1%
H
10.4
120.1
|
L
 -83.2%
H
10.4
173.3
|
L
 -76.9%
H
10.4
173.3
|
L
 73.8%
H
8
181.8
|
| Sutro Biopharma Inc |
|
125.4
|
14.7
|
L
 -1.3%
H
14.3
14.8
|
L
 -9.8%
H
14.1
16.9
|
L
 32.6%
H
10.2
17.3
|
L
 40.2%
H
7.2
17.3
|
L
 -21.7%
H
5.2
21.3
|
L
 -80.4%
H
5.2
74.8
|
L
 -93.4%
H
5.2
283
|
L
H
5.2
283
|
| Supernus Pharma Inc |
|
2,788.4
|
48.6
|
L
 -0.9%
H
48.4
49.1
|
L
 -1.0%
H
47.9
50.1
|
L
 -5.1%
H
47.8
52.5
|
L
 -12.7%
H
43.1
57.7
|
L
 24.7%
H
29.2
57.7
|
L
 19.5%
H
22
57.7
|
L
 65.5%
H
22
57.7
|
L
 328.8%
H
9.5
61.3
|
| Savara Inc |
|
1,113.0
|
5.5
|
L
 -2.0%
H
5.5
5.6
|
L
 -15.3%
H
5.5
6.4
|
L
 -13.6%
H
5.5
6.5
|
L
 26.0%
H
3.9
7
|
L
 104.9%
H
1.9
7
|
L
 98.9%
H
1.6
7
|
L
 257.5%
H
1.0
7
|
L
 -80.5%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
5.1
|
0.0
|
L
 -20%
H
0.0
0.0
|
L
 -55.6%
H
0.0
0.1
|
L
 -97.3%
H
0.0
7.0
|
L
 -97.1%
H
0.0
7.0
|
L
 -90.2%
H
0.0
7.0
|
L
 -99.7%
H
0.0
16
|
L
 -99.9%
H
0.0
128
|
L
H
0.0
2335
|
| Sanofi (ADR) |
|
113,470.0
|
47.0
|
L
 1.7%
H
46.9
47.2
|
L
 1.0%
H
45.7
47.9
|
L
 -2.8%
H
45.3
49.3
|
L
 -7.3%
H
45.3
52.7
|
L
 -9.9%
H
44.6
60.1
|
L
 -3.1%
H
42.6
60.1
|
L
 -0.5%
H
36.9
60.1
|
L
 12.8%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
376.2
|
7.0
|
L
 0.3%
H
6.9
7.2
|
L
 18.8%
H
5.9
7.4
|
L
 31.0%
H
4.7
7.4
|
L
 35%
H
4.1
7.8
|
L
 55.3%
H
2.8
7.8
|
L
 126.5%
H
1.0
10.5
|
L
 -61.0%
H
1.0
23.0
|
L
 -98.1%
H
1.0
465.2
|
| Tarsus Pharma Inc |
|
2,719.3
|
64.1
|
L
 -2.5%
H
62.7
66.4
|
L
 -9.8%
H
62.7
72.1
|
L
 -21.9%
H
62.7
83.9
|
L
 -5.1%
H
62.7
85.3
|
L
 20.7%
H
38.5
85.3
|
L
 297.4%
H
11.3
85.3
|
L
 69.9%
H
10.8
85.3
|
L
H
10.8
85.3
|
| Theravance Biopharma Inc |
|
975.4
|
19.3
|
L
 0.4%
H
19
19.3
|
L
 -7.2%
H
18.8
20.8
|
L
 2.9%
H
17.6
21.0
|
L
 35.9%
H
14.1
21.0
|
L
 99.9%
H
7.9
21.0
|
L
 77.1%
H
7.4
21.0
|
L
 3.3%
H
6.1
22.7
|
L
 17.2%
H
6.1
43.4
|
| Tenax Therapeutics Inc |
|
81.0
|
13.0
|
L
 -2.9%
H
12.8
13.8
|
L
 -12.2%
H
12.8
15.6
|
L
 6.6%
H
10.9
18.4
|
L
 79.5%
H
6.5
18.4
|
L
 112.8%
H
4.6
18.4
|
L
 -92.8%
H
2.8
344
|
L
 -99.6%
H
2.8
4864
|
L
 -100.0%
H
2.8
94080
|
| TG Therapeutics Inc |
|
4,737.4
|
29.8
|
L
 -0.5%
H
29.7
30.3
|
L
 -5.7%
H
29.7
32.6
|
L
 -2.3%
H
26.9
33.2
|
L
 -11.7%
H
26.9
36.7
|
L
 -10.6%
H
25.3
46.5
|
L
 104.0%
H
6.5
46.5
|
L
 -38.2%
H
3.5
56.5
|
L
 265.2%
H
3.3
56.7
|
| Alpha Teknova Inc |
|
150.4
|
2.8
|
L
 -1.1%
H
2.8
2.8
|
L
 -15.6%
H
2.8
3.5
|
L
 -27.4%
H
2.8
4.3
|
L
 -47.8%
H
2.8
5.4
|
L
 -69.4%
H
2.8
10
|
L
 -53.5%
H
1.2
10.4
|
L
H
1.2
30.9
|
L
H
1.2
30.9
|
| Tiziana Life Sciences Ltd |
|
193.4
|
1.5
|
L
 -5%
H
1.5
1.6
|
L
 -8.4%
H
1.5
1.8
|
L
 -1.9%
H
1.3
1.8
|
L
 -19.6%
H
1.3
2.0
|
L
 120.3%
H
0.6
2.6
|
L
 133.8%
H
0.4
2.6
|
L
 -58.7%
H
0.4
5.0
|
L
H
0.4
12.2
|
| Tonix Pharma Holding Corp |
|
227.0
|
17.8
|
L
 -2.6%
H
17.8
18.6
|
L
 -6.6%
H
17.2
19.0
|
L
 9.0%
H
14.9
20.0
|
L
 -4.4%
H
13.7
20.6
|
L
 -58.7%
H
0.2
70.0
|
L
 -99.9%
H
0.2
26600
|
L
 -100.0%
H
0.2
1356800
|
L
 -100.0%
H
0.2
3187200000
|
| Tenaya Therapeutics Inc |
|
164.5
|
0.8
|
L
 -3.8%
H
0.8
0.8
|
L
 1.3%
H
0.7
0.8
|
L
 5.6%
H
0.7
0.8
|
L
 -46.9%
H
0.7
1.6
|
L
 -27.6%
H
0.4
2.4
|
L
 -77.8%
H
0.4
8.1
|
L
H
0.4
32
|
L
H
0.4
32
|
| Tempest Therapeutics Inc |
|
13.5
|
2.8
|
L
 -2.1%
H
2.7
2.8
|
L
 -10.4%
H
2.6
3.1
|
L
 -5.8%
H
2.4
3.2
|
L
 -74.6%
H
2.4
10.9
|
L
 205.6%
H
0.4
12.2
|
L
 34.8%
H
0.2
12.2
|
L
 -90.7%
H
0.2
41.6
|
L
 -99.8%
H
0.2
2623.5
|
| Travere Therapeutics Inc |
|
2,822.9
|
31.6
|
L
 -1.4%
H
30.9
32.0
|
L
 6.1%
H
29
32.1
|
L
 -18.9%
H
22.6
40.8
|
L
 5.2%
H
22.6
42.1
|
L
 54.3%
H
12.9
42.1
|
L
 44.2%
H
5.1
42.1
|
L
 25.0%
H
5.1
42.1
|
L
 110.8%
H
5.1
42.1
|
| TherapeuticsMD Inc |
|
25.5
|
2.2
|
L
 -4.4%
H
2.2
2.4
|
L
 -13.7%
H
2.1
3.0
|
L
 31.0%
H
1.6
3.0
|
L
 81.8%
H
1.1
3.0
|
L
 103.7%
H
0.7
3.0
|
L
 -58.8%
H
0.7
5.5
|
L
 -97.3%
H
0.7
137.5
|
L
 -99.4%
H
0.7
464.5
|
| Universe Pharma INC |
|
2.3
|
4.2
|
L
H
4.2
4.2
|
L
 -2.8%
H
4
4.4
|
L
 -5.9%
H
3.8
4.6
|
L
 -13.7%
H
3.3
7.2
|
L
 824.4%
H
0.1
11
|
L
 -67.0%
H
0.1
64.8
|
L
H
0.1
179.9
|
L
H
0.1
179.9
|
| United Therapeutics Corp |
|
19,916.3
|
462.6
|
L
 -1.1%
H
462.4
468.7
|
L
 -2.0%
H
462.4
479.4
|
L
 -8.0%
H
455.6
512.7
|
L
 1.6%
H
430.0
520.0
|
L
 24.1%
H
267.0
520.0
|
L
 78.1%
H
204.4
520.0
|
L
 182.4%
H
155.7
520.0
|
L
 275.5%
H
74.3
520.0
|
| Vericel Corp |
|
1,836.8
|
36.3
|
L
 -0.5%
H
35.9
37.2
|
L
 -7.2%
H
35.6
39.5
|
L
 -3.4%
H
35.3
41.7
|
L
 4.1%
H
33.8
43
|
L
 -38.4%
H
29.2
63
|
L
 27.3%
H
26.9
63
|
L
 -12.0%
H
17.3
68.9
|
L
 1621.3%
H
1.8
68.9
|
| Veru Inc |
|
42.1
|
2.6
|
L
 0.4%
H
2.6
2.7
|
L
 -2.6%
H
2.5
2.8
|
L
 18.6%
H
2.1
2.8
|
L
 -25.1%
H
2.1
3.1
|
L
 -57.1%
H
2.1
7.4
|
L
 -95.6%
H
2.1
63.4
|
L
 -97.0%
H
2.1
245.7
|
L
 -79.7%
H
2.1
245.7
|
| Dogwood Therapeutics Inc |
|
92.1
|
2.9
|
L
 -1.0%
H
2.9
3.0
|
L
 -6.5%
H
2.8
3.5
|
L
 -31.7%
H
2.6
4.3
|
L
 -53.5%
H
2.6
7.0
|
L
 -76.1%
H
2.6
15
|
L
 796.9%
H
0.1
29.3
|
L
 -57.7%
H
0.1
29.3
|
L
H
0.1
29.3
|
| Viking Therapeutics Inc |
|
3,324.4
|
29.4
|
L
 -2.7%
H
29.2
30.6
|
L
 -13.7%
H
29.2
34.4
|
L
 -19.3%
H
29.2
36.7
|
L
 -16.5%
H
29.2
43.2
|
L
 -12.0%
H
18.9
43.2
|
L
 243.2%
H
8.3
99.4
|
L
 302.3%
H
2.0
99.4
|
L
 1313.9%
H
0.9
99.4
|
| Vanda Pharma Inc |
|
448.0
|
7.6
|
L
 -2.6%
H
7.5
7.8
|
L
 -6.4%
H
7.5
8.3
|
L
 5.3%
H
6.9
9.6
|
L
 40.1%
H
4.3
9.6
|
L
 67.3%
H
3.8
9.6
|
L
 -0.9%
H
3.3
9.6
|
L
 -47.1%
H
3.3
21.9
|
L
 -11.1%
H
3.3
33.4
|
| Verrica Pharma Inc |
|
113.5
|
7.1
|
L
 -1.5%
H
7.1
7.3
|
L
 -8.2%
H
7.1
7.9
|
L
 -13.4%
H
7.1
9.0
|
L
 96.7%
H
3.3
9.8
|
L
 886.1%
H
0.4
9.8
|
L
 50.7%
H
0.4
11.4
|
L
 -39.6%
H
0.4
18.4
|
L
H
0.4
23.3
|
| Viridian Therapeutics Inc |
|
3,095.6
|
32.5
|
L
 -3.3%
H
31.8
33.5
|
L
 0.9%
H
31.4
34.2
|
L
 2.9%
H
29.0
34.3
|
L
 41.1%
H
22.1
34.3
|
L
 67.1%
H
9.9
34.3
|
L
 -10.7%
H
9.9
38
|
L
 82.2%
H
9.5
39
|
L
 -73.8%
H
4.7
270
|
| Vertex Pharma |
|
119,458.4
|
470.8
|
L
 -1.0%
H
469.2
475.7
|
L
 0.7%
H
462.7
485
|
L
 2.4%
H
429
487.5
|
L
 12.9%
H
403.2
487.5
|
L
 6.6%
H
362.5
519.7
|
L
 46.5%
H
283.6
519.9
|
L
 105.5%
H
176.4
519.9
|
L
 418.8%
H
71.5
519.9
|
| Viatris |
|
14,926.9
|
13.0
|
L
 -0.8%
H
12.9
13.1
|
L
 -2.1%
H
12.9
13.4
|
L
 4.8%
H
12.2
13.5
|
L
 26.2%
H
9.9
13.5
|
L
 14.4%
H
6.9
13.5
|
L
 9.0%
H
6.9
13.6
|
L
 -23.7%
H
6.9
18.7
|
L
 -75.4%
H
6.9
53.2
|
| vTv Therapeutics Inc (Class A) |
|
134.9
|
34.3
|
L
 0.3%
H
32.2
35
|
L
 2.1%
H
32.2
37
|
L
 -9.8%
H
31.8
44
|
L
 62.6%
H
20.0
44
|
L
 140.4%
H
14
44
|
L
 3359.6%
H
0.4
44
|
L
 1578.9%
H
0.4
44
|
L
 372.4%
H
0.4
44
|
| VYNE Therapeutics Inc |
|
18.6
|
0.6
|
L
 -1.8%
H
0.6
0.6
|
L
 -3.5%
H
0.6
0.6
|
L
H
0.6
0.6
|
L
 60%
H
0.3
0.8
|
L
 -77.6%
H
0.3
2.9
|
L
 -87.8%
H
0.3
8.7
|
L
 -99.6%
H
0.3
237.6
|
L
H
0.3
2869.9
|
| Vaccitech PLC (ADR) |
|
27.8
|
0.7
|
L
 -2.7%
H
0.7
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 4.4%
H
0.7
0.8
|
L
 -45.9%
H
0.7
1.4
|
L
 -23.4%
H
0.7
2.9
|
L
 -75.6%
H
0.7
5.1
|
L
H
0.7
18.0
|
L
H
0.7
18.0
|
| Xenetic Biosciences Inc |
|
5.3
|
2.3
|
L
 -0.9%
H
2.3
2.4
|
L
 -16.6%
H
2.3
2.8
|
L
 13.8%
H
2.0
2.8
|
L
 -32.5%
H
1.9
3.5
|
L
 -45%
H
1.9
13.9
|
L
 -59.9%
H
1.9
13.9
|
L
 -90.3%
H
1.9
56.8
|
L
 -99.8%
H
1.9
1782
|
| Xenon Pharma Inc |
|
3,189.9
|
41.3
|
L
 -1.2%
H
40.8
42.1
|
L
 -2.3%
H
40.8
43.7
|
L
 -6.9%
H
39.3
46.4
|
L
 -2.4%
H
37.2
46.6
|
L
 2.7%
H
26.7
46.6
|
L
 9.6%
H
26.7
51.0
|
L
 187.7%
H
14.3
51.0
|
L
 524.5%
H
2.1
51.0
|
| Xilio Therapeutics Inc |
|
39.2
|
0.6
|
L
 -4.9%
H
0.6
0.6
|
L
 -6.5%
H
0.6
0.7
|
L
 -10.8%
H
0.6
0.7
|
L
 -28.4%
H
0.6
0.9
|
L
 -19.4%
H
0.6
1.7
|
L
 -86.4%
H
0.5
4.5
|
L
H
0.5
28.0
|
L
H
0.5
28.0
|
| XOMA Corp |
|
303.4
|
24.5
|
L
 -1.9%
H
24.3
25.3
|
L
 -9.0%
H
24.1
27.6
|
L
 -3.0%
H
24.1
30.8
|
L
 -26.5%
H
24.1
34.9
|
L
 -7.6%
H
18.4
39.9
|
L
 17.5%
H
13.5
39.9
|
L
 -32.4%
H
13.5
44.5
|
L
 21.3%
H
4.0
46.3
|
| XORTX Therapeutics Inc |
|
3.5
|
0.5
|
L
 2.0%
H
0.5
0.5
|
L
 -10.7%
H
0.5
0.6
|
L
 -16.7%
H
0.5
0.6
|
L
 -23.1%
H
0.5
0.7
|
L
 -47.4%
H
0.5
1.4
|
L
 -18.0%
H
0.3
7
|
L
 -81.6%
H
0.3
8.2
|
L
H
0.3
8.2
|
| Zevra Therapeutics Inc |
|
497.1
|
8.8
|
L
 -0.3%
H
8.7
8.9
|
L
 -2.8%
H
8.5
9.6
|
L
 0.1%
H
8.1
9.6
|
L
 -12.8%
H
8.0
10.6
|
L
 12.3%
H
6.2
13.2
|
L
 60.3%
H
3.9
13.2
|
L
 46.4%
H
3.9
18.2
|
L
 -96.3%
H
1.9
316
|
| Zymeworks BC Inc |
|
1,695.5
|
22.5
|
L
 0.5%
H
22
22.6
|
L
 -4.5%
H
22
23.8
|
L
 -15.9%
H
22
27.1
|
L
 16.1%
H
16
28.5
|
L
 53.9%
H
9.0
28.5
|
L
 134.8%
H
6.0
28.5
|
L
 -33.5%
H
4.1
43.3
|
L
H
4.1
59.0
|
| Sagimet Biosciences Inc (Class A) |
|
165.5
|
5.1
|
L
 -5.0%
H
5.1
5.3
|
L
 -19.8%
H
5.0
6.5
|
L
 -13.9%
H
5.0
6.6
|
L
 -38.9%
H
5.0
8.8
|
L
 25.7%
H
1.7
11.4
|
L
 -33.2%
H
1.7
20.7
|
L
 -33.2%
H
1.7
20.7
|
L
 -33.2%
H
1.7
20.7
|
| CervoMed Inc |
|
46.2
|
5.0
|
L
 -3.5%
H
4.9
5.2
|
L
 -24.2%
H
4.9
6.6
|
L
 -36.2%
H
4.9
8.3
|
L
 -27.5%
H
4.9
10
|
L
 118.9%
H
1.9
16.9
|
L
 -46.2%
H
1.8
26.4
|
L
 -94.2%
H
1.8
138.8
|
L
 -100.0%
H
1.8
17437.5
|
| Dianthus Therapeutics Inc |
|
2,448.6
|
56.7
|
L
 6.2%
H
52.8
57.5
|
L
 7.4%
H
48.9
57.5
|
L
 36.1%
H
35.8
57.5
|
L
 67.5%
H
32.3
57.5
|
L
 171.6%
H
13.4
57.5
|
L
 7353.9%
H
6.6
57.5
|
L
 7353.9%
H
6.6
57.5
|
L
 7353.9%
H
6.6
57.5
|
| Neumora Therapeutics Inc |
|
339.9
|
2
|
L
 -2.4%
H
2.0
2.0
|
L
 -4.8%
H
2.0
2.2
|
L
 12.4%
H
1.5
2.6
|
L
 -20%
H
1.5
3.3
|
L
 3.6%
H
0.6
3.3
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
| Agape ATP Corp |
|
3.5
|
0.1
|
L
 -12.5%
H
0.1
0.1
|
L
 -12.5%
H
0.1
0.1
|
L
 -41.7%
H
0.1
0.2
|
L
 -94.3%
H
0.1
1.5
|
L
 -94.7%
H
0.1
2.6
|
L
 -95.5%
H
0.1
3.5
|
L
 -95.5%
H
0.1
3.5
|
L
 -95.5%
H
0.1
3.5
|
| Barinthus Biotherapeutics PLC. (ADR) |
|
29.4
|
0.7
|
L
H
0.7
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 4.4%
H
0.7
0.8
|
L
 -45.9%
H
0.7
1.4
|
L
 -24.2%
H
0.6
2.9
|
L
 -80.2%
H
0.6
5.1
|
L
 -80.2%
H
0.6
5.1
|
L
 -80.2%
H
0.6
5.1
|
| Onconetix Inc |
|
2.3
|
1.5
|
L
 0.7%
H
1.5
1.5
|
L
 -8.0%
H
1.4
1.7
|
L
 4.2%
H
1.4
2.3
|
L
 -58.3%
H
1.4
4
|
L
 145.9%
H
0.1
5.9
|
L
 -97.1%
H
0.1
78
|
L
 -17.6%
H
0.1
3636
|
L
 -17.6%
H
0.1
3636
|
| Talphera Inc |
|
45.2
|
1.0
|
L
H
1.0
1.0
|
L
 -4.0%
H
1.0
1.0
|
L
 -9.4%
H
1.0
1.3
|
L
 -21.1%
H
1.0
1.6
|
L
 38.6%
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
| ArriVent BioPharma Inc |
|
929.7
|
22.5
|
L
 0.1%
H
22.2
22.8
|
L
 -10.6%
H
22.2
25.8
|
L
 6.5%
H
18.2
26
|
L
 20.6%
H
17
26
|
L
 -22.4%
H
15.5
29.7
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
| Skye Bioscience Inc |
|
30.8
|
1.0
|
L
H
0.9
1.0
|
L
 -8.6%
H
0.9
1.1
|
L
 23.1%
H
0.7
1.2
|
L
 -39.2%
H
0.7
1.6
|
L
 -72.0%
H
0.7
5.8
|
L
H
0.7
7.2
|
L
H
0.7
7.2
|
L
H
0.7
7.2
|
| Actuate Therapeutics Inc |
|
108.8
|
4.7
|
L
 -1.3%
H
4.7
4.9
|
L
 -14.1%
H
4.6
5.8
|
L
 -20.1%
H
4.6
7.1
|
L
 -27.4%
H
4.6
7.9
|
L
 -46.8%
H
4.6
12.0
|
L
H
4.6
12.0
|
L
H
4.6
12.0
|
L
H
4.6
12.0
|
| Bicara Therapeutics Inc |
|
908.8
|
16.6
|
L
 -1.9%
H
16.5
17.2
|
L
 -5.7%
H
16.1
18.0
|
L
 0.5%
H
15.6
18.4
|
L
 4.5%
H
13.7
19.7
|
L
 41.1%
H
7.8
19.7
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
| Gelteq Ltd |
|
10.6
|
1.0
|
L
 -2.0%
H
1.0
1.0
|
L
 -15.4%
H
1.0
1.2
|
L
 17.9%
H
0.7
1.4
|
L
 -17.5%
H
0.7
1.4
|
L
 -64%
H
0.7
4.1
|
L
H
0.7
5.5
|
L
H
0.7
5.5
|
L
H
0.7
5.5
|
| Septerna Inc |
|
1,056.7
|
23.6
|
L
 -0.8%
H
23.4
23.9
|
L
 -11.5%
H
23.4
26.8
|
L
 -16.8%
H
23.4
29
|
L
 7.6%
H
17.6
30.5
|
L
 51.8%
H
4.2
30.5
|
L
H
4.2
30.5
|
L
H
4.2
30.5
|
L
H
4.2
30.5
|
| Alpha Cognition Inc |
|
118.1
|
5.4
|
L
 4.8%
H
5.2
5.4
|
L
 -4.7%
H
5.2
6.0
|
L
 -14.9%
H
5.2
6.9
|
L
 -17.4%
H
5.0
6.9
|
L
 -14.1%
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
| Atlantic Intl Corp |
|
232.3
|
3.3
|
L
 -3.5%
H
3.3
3.3
|
L
 -12.8%
H
2.8
4
|
L
 153.5%
H
1.3
4
|
L
 22.9%
H
1.2
4
|
L
 25.8%
H
1.2
5.3
|
L
 25.8%
H
1.2
5.3
|
L
 25.8%
H
1.2
5.3
|
L
 25.8%
H
1.2
5.3
|
| BeiGene Ltd (ADR) |
|
38,160.4
|
344.9
|
L
 -1.5%
H
343.9
350.0
|
L
 1.8%
H
334.4
353
|
L
 11.1%
H
302.1
353.1
|
L
 9.5%
H
299.5
385.2
|
L
 52.1%
H
196.5
385.2
|
L
 86.7%
H
172.7
385.2
|
L
 86.7%
H
172.7
385.2
|
L
 86.7%
H
172.7
385.2
|
| Jupiter Neurosciences Inc |
|
18.2
|
0.5
|
L
 -11.7%
H
0.5
0.6
|
L
 -43.6%
H
0.5
0.9
|
L
 -52.3%
H
0.5
1.2
|
L
 -62.9%
H
0.5
1.5
|
L
 -8.6%
H
0.5
3.3
|
L
 -8.6%
H
0.5
3.3
|
L
 -8.6%
H
0.5
3.3
|
L
 -8.6%
H
0.5
3.3
|
| Ascentage Pharma Grp Intl (ADR) |
|
2,299.0
|
24.7
|
L
 -1.1%
H
24.7
24.8
|
L
 -5.6%
H
24.7
26.5
|
L
 -4.6%
H
24.7
28.8
|
L
 -26.0%
H
24.7
34.5
|
L
 42.7%
H
17.1
48.5
|
L
 42.3%
H
17
48.5
|
L
 42.3%
H
17
48.5
|
L
 42.3%
H
17
48.5
|
| Maze Therapeutics Inc |
|
2,138.9
|
44.5
|
L
 -1.2%
H
43.8
45.7
|
L
 -3.8%
H
42.2
47.4
|
L
 9.6%
H
37.4
47.4
|
L
 42.2%
H
27.0
47.4
|
L
H
6.7
47.4
|
L
H
6.7
47.4
|
L
H
6.7
47.4
|
L
H
6.7
47.4
|
| Aardvark Therapeutics Inc |
|
277.2
|
12.7
|
L
 -4.6%
H
12.7
13.8
|
L
 -15.6%
H
12.7
15.7
|
L
 -5.4%
H
12.5
16.6
|
L
 11.0%
H
8.8
16.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
| Cuprina Holdings (Cayman) Ltd (Class A) |
|
9.7
|
0.5
|
L
 -4.3%
H
0.5
0.5
|
L
H
0.4
0.5
|
L
 4.7%
H
0.4
0.5
|
L
 -50%
H
0.4
1.0
|
L
H
0.4
9.5
|
L
H
0.4
9.5
|
L
H
0.4
9.5
|
L
H
0.4
9.5
|
| Jyong Biotech Ltd |
|
190.8
|
2.6
|
L
 0.4%
H
2.6
2.7
|
L
 -18.7%
H
2.5
3.2
|
L
 -7.6%
H
2.5
5.4
|
L
 -94.9%
H
2.5
52.0
|
L
 -74.6%
H
2.5
67
|
L
 -74.6%
H
2.5
67
|
L
 -74.6%
H
2.5
67
|
L
 -74.6%
H
2.5
67
|
| Black Titan Corp |
|
16.4
|
1.8
|
L
 -5.8%
H
1.8
1.9
|
L
 -26.8%
H
1.8
2.6
|
L
 11.1%
H
1.5
3.3
|
L
 -53.9%
H
1.5
10.1
|
L
 -92.5%
H
1.5
23.5
|
L
 -92.5%
H
1.5
23.5
|
L
 -92.5%
H
1.5
23.5
|
L
 -92.5%
H
1.5
23.5
|
| MapLight Therapeutics Inc |
|
805.4
|
17.8
|
L
 -4.5%
H
17.5
18.6
|
L
 -4.5%
H
17.1
19.5
|
L
 0.1%
H
15.6
20.5
|
L
 7.3%
H
12.2
21.6
|
L
 -3.2%
H
12.2
21.6
|
L
 -3.2%
H
12.2
21.6
|
L
 -3.2%
H
12.2
21.6
|
L
 -3.2%
H
12.2
21.6
|
| NovaBridge Biosciences ADR |
|
405.8
|
3.5
|
L
 -4.4%
H
3.5
3.7
|
L
 -9.5%
H
3.5
4.1
|
L
 -12.7%
H
3.4
5.2
|
L
 -22.6%
H
3.4
5.2
|
L
 -22.6%
H
3.4
5.2
|
L
 -22.6%
H
3.4
5.2
|
L
 -22.6%
H
3.4
5.2
|
L
 -22.6%
H
3.4
5.2
|
| Evommune Inc |
|
693.2
|
22.0
|
L
 1.6%
H
21.5
23
|
L
 16.4%
H
17.7
23.3
|
L
 22.2%
H
14.8
23.3
|
L
 8.7%
H
13.9
24.0
|
L
 8.7%
H
13.9
24.0
|
L
 8.7%
H
13.9
24.0
|
L
 8.7%
H
13.9
24.0
|
L
 8.7%
H
13.9
24.0
|
| Aktis Oncology Inc |
|
-
|
20.0
|
L
 1.6%
H
19.2
20.4
|
L
 -10.9%
H
19.2
22.5
|
L
 -10.9%
H
18.5
24.5
|
L
 -10.9%
H
18.5
24.5
|
L
 -10.9%
H
18.5
24.5
|
L
 -10.9%
H
18.5
24.5
|
L
 -10.9%
H
18.5
24.5
|
L
 -10.9%
H
18.5
24.5
|
| Helus Pharma Inc |
|
-
|
6.7
|
L
 -1.0%
H
6.6
6.9
|
L
 -13.1%
H
6.6
7.8
|
L
 -11.0%
H
6.6
8.2
|
L
 -11.0%
H
6.6
8.2
|
L
 -11.0%
H
6.6
8.2
|
L
 -11.0%
H
6.6
8.2
|
L
 -11.0%
H
6.6
8.2
|
L
 -11.0%
H
6.6
8.2
|
| NervGen Pharma Corp |
|
327.9
|
4.1
|
L
 -0.7%
H
4.1
4.3
|
L
 -20.7%
H
4
5.2
|
L
 -28%
H
4
5.9
|
L
 -28%
H
4
5.9
|
L
 -28%
H
4
5.9
|
L
 -28%
H
4
5.9
|
L
 -28%
H
4
5.9
|
L
 -28%
H
4
5.9
|